Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2016

Discriminative Stimulus Properties of Endogenous Cannabinoid
Degradative Enzyme Inhibitors
Robert Owens II

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Pharmacology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/4413

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

Discriminative Stimulus Properties of Endogenous Cannabinoid Degradative Enzyme Inhibitors

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University

By
Allen Owens

Bachelor’s of Science, North Carolina Agricultural and Technical State University, 2009

Director: Dr. Aron Lichtman, Professor, Department of Pharmacology & Toxicology; Associate
Dean of Research and Graduate Studies, School of Pharmacy

Virginia Commonwealth University
Richmond, Virginia
April 2016

Acknowledgements
The author wishes to thank several people. I would like to thank my dissertation advisor
Dr. Aron Lichtman for allowing me to join his lab as a post-baccalaureate student in 2010, and
sticking with me as a doctoral student. There have been many ups and downs during my graduate
training, and he has always been a staunch supporter of me and of my career aspirations. In
addition to his positive influence on my scientific training, Dr. Lichtman has been an excellent
mentor and has become a second father figure. Words cannot express how thankful I am, and a
large portion of my future career accomplishments will be because of him. Additionally, I would
like to thank all of my committee members (Drs. Francine Cabral, Patrick Beardsley, Imad
Damaj, Joe Porter, Suzanne Barbour) for your willingness to participate on my committee. Dr.
Beardsley and Dr. Porter, thank you for our one on one conversations to help me understand
some of the more debatable concepts in drug discrimination, and for your feedback on my
manuscript. Dr. Cabral, you have always brought positive energy to our meetings, and our
personal interactions when we crossed paths in the cafeteria, when I needed it the most.
Thank you to my big four. In the sport of professional basketball, there has been a
common idea over the past several years, that a team with a nucleus of three superstars will have
a very good chance of winning a championship. Instead of a big three, I have a big four (Drs.
Lichtman, Lloyd, Barbour, Wu-Pong) that have been crucial to getting me to my dissertation
defense (my personal championship game) on July 15th and preparing me for the next chapter in
my life. Dr. Lloyd has done a tremendous job running the VCU post-baccalaureate research

2

program. The PREP program gave me the opportunity to spend one year in Dr. Lichtman’s lab
after undergrad to learn how to conduct graduate level research, and determine if I wanted to
pursue a Ph.D. Dr. Barbour was someone who I could confide in, share my struggles, and
provided an enormous amount of support and guidance. Without her presence, I’m not sure if I
would have made it past the first year of graduate school. Dr. Wu-Pong opened my eyes to a
larger world, and established a program to help students that will not have careers in academia,
but instead choose non-traditional career paths to discover their best self, and have more
confidence in their career goals. I believe most people will fall into non-traditional paths by
serendipity, and Dr. Wu-Pong has made this process more natural.
Last but certainly not least, I want to thank my parents. My mom is one of the hardest
working women I have met in my entire life. From the family farm picking cotton, vegetables
and raising livestock, to quality control manager at Asahi Kasei, her work ethic has always been
second to none. After being diagnosed with breast cancer, she drove from work during her lunch
breaks to receive chemotherapy and immediately went back to work, never using her situation as
an excuse to miss work. My father was born in the Deep South during the time period of Jim
Crow and was able to escape poverty and obtain a very respectable career in banking. Above all,
my parents have inspired me to never quit.

3

Table of Contents
Acknowledgements ......................................................................................................................... 2

Table of Contents ............................................................................................................................ 4

List of Tables .................................................................................................................................. 6

List of Figures ................................................................................................................................. 7

List of Abbreviations ...................................................................................................................... 8

Abstract ......................................................................................................................................... 11

Chapter 1. Introduction ................................................................................................................. 13

Investigating the psychoactive effects of cannabinoids ............................................................ 27
Overview of cannabinoid drug discrimination ......................................................................... 35
Discriminative Stimulus Properties of Cannabinoid Antagonists ............................................ 40
Discriminative Stimulus Properties of Phytocannabinoids....................................................... 41
Discriminative Stimulus Properties of Endogenous Cannabinoids .......................................... 43
Rationale and Hypothesis ............................................................................................................. 54

Chapter 2. Characterization of the SA-57 discriminative stimulus .............................................. 57
4

Introduction ............................................................................................................................... 57
Materials and methods .............................................................................................................. 60
Drug Discrimination Paradigm ................................................................................................. 61
Results ....................................................................................................................................... 65
Discussion ................................................................................................................................. 88
Chapter 3. General Discussion ...................................................................................................... 93

References ................................................................................................................................... 102

5

List of Tables
Table 1 Evaluation of self-administration (SA) of cannabinoids in laboratory animals ........................... 31
Table 2 Evaluation of intracranial self-stimulation of cannabinoids in laboratory animals....................... 33
Table 3 Evaluation of conditioned place preference (CPP) of cannabinoids in laboratory animals........... 34
Table 4 Evaluation of discriminative stimulus properties of cannabinoids in laboratory animals ............. 47

6

List of Figures
Figure 1. Effects of CP 55,940, AEA and SA-57 on percentage of responses in training drugpaired apertures and response rates in C57BL/6J mice trained to discriminate CP 55,940 (0.1
mg/kg) or FAAH (-/-) mice trained to discriminate AEA (6 mg/kg). .......................................... 66
Figure 2. Acquisition rates of SA-57 (10 mg/kg) in C57BL/6J mice, AEA (10 mg/kg) in FAAH
(-/-) mice, and CP 55,940 (0.1 mg/kg) in C57BL/6J mice trained in drug discrimination. .......... 68
Figure 3. Time course effects for occasioning the 10 mg/kg SA-57 training dose. ..................... 70
Figure 4. CB1 receptors play a necessary role in the SA-57 discriminative stimulus. ................. 72
Figure 5. SA-57 does not compete with [3H] SR141716A binding to CB1 receptors in mouse
cerebellum. .................................................................................................................................... 75
Figure 6. Substitution experiments of non-cannabinoid psychoactive drugs nicotine (1.5 mg/kg)
and diazepam (10 mg/kg) for the SA-57 training dose. ................................................................ 77
Figure 7. Evaluation of the dose-response relationships of SA-57, CP 55,940, and JZL195 to
occasion the SA-57 (10 mg/kg) discriminative stimulus. ............................................................. 79
Figure 8. Evaluation of the dose-response relationships of SA-57, MJN110 and JZL184 to
occasion the SA-57 (10 mg/kg) stimulus. ..................................................................................... 81
Figure 9. Substitution of MJN110 (5 mg/kg), JZL184 (100 mg/kg) and JZL195 (20 mg/kg) for
SA-57 (10 mg/kg) requires CB1 receptors. ................................................................................... 83
Figure 10. The FAAH inhibitor PF-3845 augments the MJN110 substitution dose-response curve
for SA-57 (10 mg/kg).................................................................................................................... 87

7

List of Abbreviations

2-AG

2-arachidonoylglycerol

AA

arachidonic acid

ABHD

α/β hydrolase

AC

adenylyl cyclase

AEA

anandamide

ANOVA

analysis of variance

Bmax

Maximal specific binding sites

cAMP

Cyclic adenosine monophosphate

CB1

Cannabinoid receptor, subtype 1

CB2

Cannabinoid receptor, subtype 2

DAGL

Diacylglycerol lipase

eCB

endocannabinoid

FAAH

Fatty acid amide hydrolase

G-protein

Guanine nucleotide binding protein

Gi

cAMP inhibitory G-protein

8

GPCR

G-protein coupled receptor

i.p.

Intraperitoneal

JZL184

4-nitrophenyl-4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)
piperidine1-carboxylate

JZL195

4-nitrophenyl 4-(3-phenoxybenzyl) piperazine-1-carboxylate

KT195

([4-(4′-Methoxy[1,1′-biphenyl]-4-yl)-1H-1,2,3-triazol-1-yl](2-phenyl1-piperidinyl)-methanone)

KT182

([4-[3′-(Hydroxymethyl)[1,1′-biphenyl]-4-yl]-1H-1,2,3-triazol-1-yl](2phenyl-1-piperidinyl)-methanone)

MAGL

Monoacylglycerol lipase

MJN110

(2,5-dioxopyrrolidin-1-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1carboxylate)

NAPE-PLD

N-acyl phosphatidylethanolamine phospholipase D

OEA

Oleylethanolamine

PEA

Palmitoylethanolamine

PF-3845

N-(pyridin-3-yl)-4-(3-(5-(trifluoromethyl)pyridin-2-yloxy)benzyl)
piperdine-1-carboxamide

9

Rim

Rimonabant (SR141716A)

SA-57

(4-[2-(4-Chlorophenyl)ethyl]-1-piperidinecarboxylic acid 2(methylamino)-2-oxoethyl ester)

SAMHSA

Substance Abuse and Mental Health Services Administration

s.c.

Subcutaneous

SR144528

(N-[(1S)-endo-1,3,3-trimethylbicyclo [2.2.1]heptan2-yl]-5-(4-chloro-3methylphenyl)-1-[(4-methylphenyl)methyl]-1H-pyrazole-3carboxamide)

THC

Δ9-tetrahydrocannabinol

URB597

[3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate

WIN 55, 212

(R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone

10

Abstract
DISCRIMINATIVE STIMULUS PROPERTIES OF ENDOGENOUS CANNABINOID
DEGRADATIVE ENZYME INHIBITORS
By Allen Owens, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2016
Major Director: Dr. Aron Lichtman, Professor, Department of Pharmacology & Toxicology;
Associate Dean for Research and Graduate Studies, School of Pharmacy

Inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL),
the chief degradative enzymes of N-arachidonoyl ethanolamine (anandamide; AEA) and 2arachidonoylglycerol (2-AG), respectively, elicits no or partial substitution for Δ9tetrahydrocannabinol (THC) in drug discrimination procedures. However, combined inhibition
of both enzymes fully substitutes for THC, as well as produces a full constellation of
cannabimimetic effects. Because no published report to date have investigated whether an
inhibitor of endocannabinoid hydrolysis will serve as a discriminative stimulus, the purpose of
this doctoral dissertation was to investigate whether C57BL/6J mice would learn to discriminate
SA-57 (4-[2-(4-Chlorophenyl)ethyl]-1-piperidinecarboxylic acid 2-(methylamino)-2-oxoethyl
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ester), a dual inhibitor of FAAH and MAGL, from vehicle in the drug discrimination paradigm.
Also, we sought to determine whether inhibiting both enzymes, or inhibiting one enzyme was
necessary to generate the SA-57 discriminative stimulus. Initial experiments showed that SA-57
fully substituted for either CP 55,940 ((-)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans4-(3-hydroxypropyl)cyclohexanol), a high efficacy CB1 receptor agonist in C57BL/6J, mice or
AEA in FAAH

(-/-)

mice. The majority (i.e., 23 of 24) of subjects achieved criteria of

discriminating SA-57 (10 mg/kg) from vehicle within 40 sessions, with full generalization
occurring 1-2 h post injection. CP 55,940, the dual FAAH-MAGL inhibitor JZL195 (4nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate), the MAGL inhibitors MJN110 (2,5dioxopyrrolidin-1-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate) and JZL184 (4[Bis(1,3-benzodioxol-5-yl)hydroxymethyl]-1-piperidinecarboxylic acid 4-nitrophenyl ester) fully
substituted for SA-57. Although, the FAAH inhibitors PF-3845 and URB597 did not substitute
for SA-57, PF3845 produced a two-fold leftward shift in the MJN110 substitution dose-response
curve. In addition, the CB1 receptor antagonist rimonabant blocked the generalization of SA-57
as well as substitution of CP 55,940, JZL195, MJN110, JZL184 for the SA-57 discriminative
stimulus. These findings taken together indicate that the inhibition of endocannabinoidregulating enzymes serve as breaks to prevent overstimulation of CB1 receptors, and MAGL
inhibition is the major driving force for generating the SA-57 discriminative stimulus.
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Chapter 1. Introduction

Cannabis sativa (marijuana) has been cultivated for thousands of years for its therapeutic
benefits, but its rewarding properties contribute to it being the most widely abused illicit drug in
the United States (NIDA-SAMHSA, 2014). Currently, half of the United States permit legal
provisions for the use of cannabis for assorted therapeutic purposes (i.e. nausea, glaucoma, pain,
chemotherapy-induced nausea and vomiting). Recently, Colorado, Washington and the District
of Columbia decriminalized the recreational use of marijuana and on November 8th 2016, the
state of California will enter a ballot initiative to decriminalize marijuana.
Marijuana contains over 500 identified constituents, and approximately 109 of its
constituents are classified as cannabinoids (Mehmedic et al., 2010). Δ9-Tetrahydrocannabinol
(THC) is the most widely investigated cannabinoid, and is the main psychoactive constituent in
marijuana. Other widely investigated cannabinoids include cannabinol (CBN), which was
discovered from the Indian hemp at the end of the 19th century (Wood et al., 1899) and the nonpsychoactive cannabinoid cannabidiol (CBD) (Mechoulam and Gaoni, 1965) and Δ9tetrahydrocannabivarin (THCV) (Merkus, 1971) (see table 1). In 1964, the chemical structure of
THC was elucidated (Gaoni and Mechoulam, 1964a), which led to a renaissance in the
cannabinoid field of research.
The recreational use of marijuana in the 1960s sparked research efforts to investigate the
pharmacological and physiological effects of marijuana. Cannabinoids produce a variety of
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pharmacological effects in humans and laboratory animals. Collectively, several effects are more
unique to cannabinoids than drugs from other classes such as elevated heart rate, ataxia,
analgesia, and hypothermia. An early hypothesis to explain the mechanism by which THC
produces its effects was that it disrupted neurotransmission by perturbing neuronal cell
membranes (Hillard et al., 1985). When evaluating newly synthesized cannabinoids for
behavioral activity, a battery of four tests known as the tetrad (hypoactivity, hypothermia,
antinociception, catalepsy) is used to distinguish cannabinoids from drugs in different classes
(Little et al., 1988), which was later useful in providing functional evidence for a receptor
mechanism of action. Also, cannabinoids were evaluated in rodents trained to discriminate THC
(Martin et al., 1991), which also provided additional evidence for a receptor mechanism of
action.
Following the elucidation of the structure of THC, medicinal chemists developed
synthetic cannabinoids (see table 2), which enabled further research to investigate structure
activity relationships (SARs). These SAR studies were instrumental in demonstrating that small
changes in drug structure dramatically altered drug potency, which greatly supported a receptor
mechanism of action. One synthetic cannabinoid, CP 55,940 which was synthesized by Pfizer
(Koe et al., 1985) along with other synthetic compounds such as HU-210 (Howlett et al., 1990),
and WIN55-212-2 (D’Ambra et al., 1992) helped advance cannabinoid research and understand
the mechanisms that generate their physiological effects. Synthetic cannabinoids as well as THC
have different binding affinities for the CB1 and CB2 receptors that result in differences in their
individual potencies. Unlike THC, which is a partial efficacy agonist in vitro, synthetic
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cannabinoids produced full agonist like properties (Howlett et al., 1988; Breivogel et al., 1998).
Although these early structure activity relationship studies provided important insights,
the specific mechanism of cannabinoids in the brain remained unknown. This gap in our
understanding was overcome by the discovery that cannabinoids inhibit adenylyl cyclase activity
in model neuronal systems (Howlett and Fleming, 1984; Howlett, 1985). Also, CP 55, 940 (Ki =
25 nM) (Howlett, 1987) was more potent than THC (Ki = 430 nM) at inhibiting adenylyl cyclase
(Howlett et al., 1988) and was used in the first radioligand binding studies that identified that
cannabinoids bind to a specific receptor (Devane et al., 1988). In addition, (-)-CP 55, 940 was
found to be 200-fold more potent than its positive enantiomer CP 56, 667 at inhibiting adenylate
cyclase activity and have higher affinity (Matsuda et al., 1990). Also, the inactive enantiomer
WIN 55, 212-3 of WIN 55, 212-2 was devoid of pharmacological effects in the tetrad assay
(Martin et al., 1991; Compton et al., 1992). These collective findings provided strong evidence
that cannabinoids produced their effects by through a receptor mechanism of action.
In combination with the receptor binding data, the tetrad assay was beneficial in
determining that CB1 receptors mediated the central effects of cannabinoids (Compton et al.,
1993), by comparing the structural features of cannabinoids with their in vivo activity (Wiley et
al., 2014). The pharmacological effects of cannabinoid receptor agonists showed high
correlations between the tetrad in vivo measures and CB1 receptor binding affinity, as follows:
decrease in spontaneous locomotor activity (r = 0.91), antinociception (r = 0.9), hypothermia (r =
0.89), and catalepsy (r = 0.85) (Compton et al., 1993). For example, nearly 60 different
cannabinoids were found to displace [3H] CP 55-940 from its binding site (Compton et al.,
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1996), and produced tetrad effects that correlated with binding affinity.
Receptor autoradiography studies led to the discovery that the CB1 receptor is
heterogeneously located throughout the central nervous system (CNS) (Herkenham et al., 1991),
and is responsible for the cannabimimetic side-effect profile of marijuana, which includes abuse,
dependence, and memory impairment (Lichtman et al., 1995; Hampson and Deadwyler, 1999;
Justinova et al., 2003). These effects are produced by activating G-protein coupled CB1 receptors
that inhibit adenylyl cyclase activity and dampen cAMP production (Howlett et al., 1990). In
addition, cannabinoid receptor activation attenuates N and P/Q-type calcium channels activity,
inhibits cAMP production, and the release of excitatory and inhibitory neurotransmitters. CB1
receptors are located on presynaptic GABAergic and glutamatergic neurons (Katona et al., 1999)
and the stimulation of CB1 receptors leads to a reduction in the respective neurotransmitters
GABA and glutamate.
Using both CB1 (-/-) mice and pharmacological antagonists of CB1 receptors (RinaldiCarmona et al., 1994; Compton et al., 1996), revealed that the pharmacological effects of THC
as well as synthetic cannabinoids in the tetrad are CB1 receptor mediated. Also, pharmacological
antagonists of CB1 receptors attenuate the behavioral effects of cannabinoids in the tetrad (Long
et al., 2009; Blankman and Cravatt, 2013). In addition, these genetic and pharmacological tools
were used to show that CB1 receptor activation can be attributed to several common features of
marijuana including increased feeding (Smart et al., 2000), reduced emesis and nausea (Darmani
and Pandya, 2000; Darmani, 2001), reductions in pain (Ignatowska-Jankowska et al., 2015;
Ghosh et al., 2015) and impairments in memory (Lichtman and Martin, 1996; Niyuhire et al.,
16

2007).
The second major binding site for cannabinoids is the cannabinoid receptor type-2 (CB2)
receptor (Munro et al., 1993). CB2 receptors are involved in the immune and hematopoietic
systems. CB2 receptor messenger RNA and protein are predominately expressed in microglia
(Carlisle et al., 2002) brainstem neurons (Van Sickle et al., 2005; Onaivi et al., 2006) and the
periphery (Cabral and Marciano-Cabral, 2005). Also, activation of CB2 receptors modulates
cytokine production (Klein et al., 2003), suppresses the proliferative response of T and B cells to
mitogens through the induction of apoptosis (Lombard et al., 2007), and reduces monocyte
chemotaxis through PI3K/Akt and ERK1/2 signaling (Montecucco et al., 2008). Finally, CB1 and
CB2 receptors share approximately 44% homology (Munro et al., 1993).

Table 1. Prevalent phytocannabinoids found in marijuana
Phytocannabinoid

Structure

Reference

Tetrahydrocannabinol (THC)

(Gaoni & Mechoulam, 1964)

Tetrahydrocannabivarin
(THCV)

(Merkus, 1971)
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Cannabichromene (CBC)

(Gaoni & Mechoulam, 1966)

Cannabidiol (CBD)

(Michoulam and Shvo, 1963)

Cannabigerol (CBG)

(Gaoni and Mechoulam, 1964b)

Cannabinol (CBN)

(Wood et al., 1899)
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Table 2. Synthetic cannabinoids
Synthetic
Cannabinoid

Reference

Structure

CP 55,940

Koe et al., 1985

HU-210

Howlett et al., 1990

WIN 55-212

D’Ambra et al., 1992

JWH-018

Huffman et al., 1994
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Table 3. Endocannabinoid catabolic enzyme inhibitors.
Enzyme Inhibitor

Reference

Target Enzyme

URB597

(Boger et al., 2005,
Piomelli et al., 2006)

(IC50 = 5 nM)

PF-3845

(Ahn et al., 2009)

URB524

(Mor et al., 2008)

OL-92

(Boger et al., 2005)

OL-135

(Boger et al., 2005)

KML29

(Chang et al., 2012)

Structure
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FAAH

FAAH
(IC50 = 230 nM)

FAAH
(IC50 = 63 nM)

FAAH
(IC50 = 0.28 nM)

FAAH
(IC50 = 2.1 nM)

MAGL
(IC50 = 15 nM)

JZL184

(Labar et al., 2010)

Narachidonylmaleimide

(Labar et al., 2010)

JZL195

(Long et al., 2009)

JZL184
(IC50 = 8 nM)

MAGL
(IC50 = 140 nM)

FAAH (IC
MAGL (IC

50

= 2 nM)

50

= 4 nM)

SA-57

(Niphakis et al., 2011)

FAAH (IC50 = <10 nM)
MAGL (IC50 = 410 nM)

MJN110

(Niphakis et al., 2013)

(IC50 = 2.1 nM)

MAGL

The discovery of endogenous marijuana-like molecules (endocannabinoids) represented a
significant breakthrough in cannabinoid research. The first endocannabinoid isolated from
porcine brain and identified by mass spectrometry and nuclear magnetic resonance spectroscopy
was N-arachidonylethanolamide and was named anandamide (AEA) after the Sanskrit word for
bliss (Devane et al., 1992) (see table 4). Anandamide competed with the specific binding of the
radiolabeled cannabinoid probe [3H] HU-243. The second endocannabinoid identified was 2arachidonoylglycerol (2-AG), isolated from canine intestines, and rat brain synaptysomes
21

(Mechoulam et al., 1995; Sugiura et al., 1995) (see table 4). 2-AG inhibited adenylate cyclase
production in mouse spleen, with a similar potency as THC (Mechoulam et al., 1995). Also,
intravenous administration of 2-AG produces effects commonly observed with THC in the tetrad
assay including immobility, antinociception, reduced spontaneous activity, and decreased rectal
temperature. AEA and 2-AG are synthesized on post-synaptic neurons from phospholipids and
released on demand (i.e. as needed) and travel in a retrograde manner from the post-synaptic
neuron terminal to pre-synaptic neuronal CB1 receptors.
The endocannabinoid (AEA) is synthesized and degraded through distinct biosynthetic
and degradative enzymatic pathways. The synthesis of AEA is not completely understood, but
one candidate enzyme is NAPE-phospholipase D (NAPE-PLD) (Nyilas et al., 2008) however,
NAPE-PLD

(-/-)

mice do not show reductions in N-acylethanolamines (NAES) (Simon and

Cravatt, 2010). After on demand synthesis and release into the synapse, AEA is rapidly degraded
in postsynaptic neurons by the enzyme fatty acid amide hydrolase (FAAH) (Cravatt et al., 1996;
Giang and Cravatt, 1997; Gulyas et al., 2004). Efforts to determine the molecular identity of the
enzyme that degraded AEA were facilitated by a structurally related bioactive lipid oleamide
(Cravatt et al., 1995). Anandamide and the sleep-inducing lipids oleamide, had similar
hydrolysis activities in N18 neuroblastoma cells (Maurelli et al., 1995). Expression of rat brain
oleamide hydrolase confirmed that anandamide was an additional substrate of this enzyme
(Cravatt et al., 2001). In addition to AEA, FAAH regulates the levels of other ethanolamides
including palmitoylethanolamide (PEA), oleamide, and oleoylethanolamide (OEA) (Cravatt et
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al., 1995). The endogenous fatty acid amide PEA isolated from soybeans and peanuts was
discovered to have anti-inflammatory properties (Kuehl et al., 1957).

Table 4. Endogenous cannabinoids
Endogenous cannabinoid

Structure

Reference

N-arachidonoylethanolamine
(AEA)

(Devane et al., 1992)

2-Arachidonoylglycerol
(2-AG)

(Mechoulam et al., 1995;
Sugiura et al., 1995)
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The biosynthesis of neuronal 2-AG is much better understood than the biosynthesis of
AEA. The synthesis of 2-AG occurs by the cleavage of diacylglygerol (DAG) by DAG lipasealpha (DAGLα) (Bisogno et al., 2003) and DAG lipase-beta (DAGLβ). These two enzymes are
differentially expressed on cells in the nervous system and peripheral tissue (Hsu et al., 2012).
DAGLα is expressed more abundantly than DAGLβ throughout the CNS (e.g. amygdala,
cerebellum, hippocampus, frontal cortex, and spinal cord). DAGLα is expressed on postsynaptic
neurons in various brain regions (Katona et al., 2006; Yoshida et al., 2006; Lafourcade et al.,
2007) and is abundant around dendritic spines which are present in postsynaptic neurons in the
cerebellum and hippocampus, and DAGLβ is expressed on macrophages and microglia (Hsu et
al., 2012). Also, brain levels of 2-AG are significantly reduced in mice devoid of (DAGLα)
compared to mice without (DAGLβ) (Gao et al., 2010; Tanimura et al., 2010).
Several studies implicated MAGL as a key regulator of 2-AG and arachidonic acid levels
in CNS. For example, overexpression of MAGL in rat neurons attenuates the accumulation of 2AG (Dinh et al., 2002). Also, depletion of MAGL in rat brain proteomes decreases 2-AG
hydrolysis by 50% (Dinh et al., 2004). The degradation of 2-AG (approximately 85%) is
regulated on the presynaptic neuron by MAGL (Blankman et al., 2007). In the rat brain, MAGL
is largely expressed in the cerebellum, cortex, thalamus, and hippocampus (Dinh et al., 2002)
and is primarily localized to presynaptic terminals (Gulyas et al., 2004). The remaining 2-AG is
degraded by the enzymes alpha/beta hydrolase domain 6 and 12 (Blankman et al., 2007).
Degradation of 2-AG results in an increase in available arachidonic acid levels in the brain,
which is a major source of prostanoids and prostaglandins (Nomura et al., 2011).
24

Later, the synthesis of pharmacological inhibitors of eCB hydrolysis, and mice devoid of
the endocannabinoid regulating enzymes provided abundant research opportunities (see table 3).
For example, FAAH inhibitors have proven to have therapeutic potential in a wide variety of preclinical assays (Piomelli et al., 2006). The FAAH inhibitor PF-3845 reduces a subset of somatic
withdrawal signs in opioid dependent mice (jumps and paw flutters) (Ramesh et al., 2011). The
FAAH inhibitor URB597 shows anxiolytic-like activity in the elevated zero maze (Kathuria et
al., 2003) and also produces antidepressant effects in forced swim assay (Gobbi et al., 2005).
Also, FAAH inhibitors display similar analgesic properties in a variety of animal models of pain
(see review)(Schlosburg et al., 2009) and reduces inflammation-induced edema (Cravatt et al.,
2004; Holt et al., 2005; Wise et al., 2008). One benefit of FAAH inhibitors is the absence of the
full set of cannabimimetic effects or THC-like subjective effects as measured in the tetrad and
drug discrimination assays (see section below on cannabinoid drug discrimination).
Genetic deletion of FAAH provided the first evidence that FAAH was the principal
hydrolytic enzyme of anandamide (Cravatt et al., 2001). Mice devoid of FAAH have
approximately 15 fold-increases in elevations of AEA in the brain of wild-type mice (Cravatt et
al., 2001) but retain normal levels of 2-AG (Osei-Hyiaman et al., 2005) and CB1 expression
(Lichtman and Martin, 2002). FAAH (–/–) mice are largely indistinguishable from wild-type mice.
Exogenous administration of anandamide produces robust effects in the tetrad (analgesia, hypomotility, hypothermia, and catalepsy) (Ahn et al., 2008). Also, FAAH regulates the levels of
other ethanolamides including palmitoylethanolamide (PEA), oleamide, and oleoylethanolamide
(OEA) (Cravatt et al., 1995). One benefit of genetically deleting FAAH over pharmacological
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inhibitors is a more direct examination without off-target drug effects, of the physiological role
of AEA in the endogenous cannabinoid system. For example, URB597, OL-135, CAY-10402
inhibits FAAH in the CNS but also target peripheral tissues. There is also the added benefit of
combining genetic with pharmacological approaches. Specifically, one study using a
complementary pharmacological and genetic approach observed that administration of AEA
exogenously to animals treated with URB597 or FAAH

(-/-)

produce tetrad behavioral effects

(Cravatt et al., 2001; Fegley et al., 2005), indicating in the absence of FAAH, exogenous AEA
can produces effects that are similar to THC.
The development of MAGL inhibitors provided a new approach to prevent 2-AG
hydrolysis and understand the physiological properties of 2-AG (see table 4). The MAGL
inhibitor JZL184 is able to elevate 2-AG levels 10-fold without elevating AEA (Long, et al.,
2009). Previous work in the Lichtman lab observed that the MAGL inhibitor JZL184 attenuated
somatic withdrawal signs (i.e. spontaneous jumping, paw flutters, wet-dog shakes) in opioid
dependent mice (Ramesh et al., 2011). In contrast to FAAH inhibition, The MAGL inhibitor
JZL184 produced increased cannabimimetic effects including antinociception, hypomotility,
hyper-reflexia, and partial THC-like subjective effects which are attenuated by the CB1
antagonist rimonabant and not observed in CB1

(-/-)

mice (Long, et al., 2009). In addition,

repeated administration of JZL184 produces pharmacological tolerance and receptor
desensitization of CB1 receptors (Schlosburg et al., 2010). Genetic deletion of MAGL and
repeated administration of JZL184 does not retain its analgesic properties and produces crosstolerance to WIN 55, 212-2 and PF-3845.
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MAGL

(−/−)

knockout mice were developed as a complementary approach to

pharmacological inhibition of MAGL. MAGL

(−/−)

mice have downregulated CB1 receptors,

approximately 90% reductions in enzymatic activity, and about a 10-fold increases in brain 2-AG
levels (Schlosburg et al., 2010). Brain levels of arachidonic acid levels are also reduced in
MAGL

(−/−)

mice (Schlosburg et al., 2010). The observation that arachidonic acid levels are

reduced in MAGL

(−/−)

is consistent with observations that that arachidonic acid levels are

decreased by organophosphorus agents that inhibit MAGL (Nomura et al., 2008). Later, it was
discovered that 2-AG is a major endocannabinoid precursor of arachidonic acid in the brain,
spleen, lung and liver (Nomura et al., 2008). These findings provided the first insights that the
endocannabinoid and eicosanoid signaling pathways might be interconnected.

Investigating the psychoactive effects of cannabinoids
The psychoactive effects of cannabinoids are attributed to the stimulation of neuronal
CB1 receptors. Laboratory assays such as intracranial self-stimulation (ICSS), self-administration
(SA), conditioned place preference (CPP), and drug discrimination (DD) are used to investigate
the abuse-related effects of drugs (Solinas et al., 2006), and the receptors that contribute to their
effects (Balster, 1991; Maldonado, 2002). Attempts to study the abuse-related effects of
cannabinoids in ICSS, SA, and CPP have proven very difficult (Maldonado, 2002), and reports
indicating that cannabinoids are rewarding or aversive are inconsistent. In the limited number of
studies that report reinforcing, or rewarding effects of cannabinoids, the observations are limited
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to one species (squirrel monkeys), one assay (self-administration), a specific lab group, or a strict
set of experimental parameters (i.e. priming injections in CPP).
In the drug self-administration paradigm, cannabinoids are not readily intravenously selfadministered in rodents or non-human primates (Mansbach and Nicholson, 1994) (See Table 1).
One explanation is that cannabinoids have a long duration of effects, with maximal plasma
concentrations of THC (1000 ng/ml) occurring immediately after exposure to smoke in rhesus
monkeys and approximately 80 ng/ml 45 minutes after exposure in humans (Slikker et al., 1991).
Commonly in THC self-administration studies, lab subjects are food-restricted before test
sessions (Takahashi and Singer, 1979; de la Garza and Johanson, 1987) or administered other
drugs of abuse (Tanda et al., 2000). The only consistent observation of intravenously selfadministered THC has been in squirrel monkeys (Justinova et al., 2003) in which squirrel
monkeys with no history of exposure to any other drugs learned to press a lever for intravenous
THC and the acquisition of THC self-administration was very rapid (Justinova et al., 2003). In
addition

to

squirrel

monkeys,

rats

self-administer

THC

if

administered

via

intracerebroventricular route of administration. In these limited examples, self-administration of
THC can be extinguished either by administering vehicle instead of THC, or the CB1 receptor
antagonist SR141716A.
In the ICSS paradigm, animals learn to respond for electrical pulses into medial forebrain
bundle, the location in the brain responsible for the rewarding effects of ICSS (See Table 2)
(Kornetsky, 1985). Many studies report that drugs of abuse lower electrical stimulation
thresholds, which suggests a similar degree of reward can be obtained with less electrical
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stimulation in the presence of a known drug that produces rewarding effects (Bauzo and
Bruijnzeel, 2012). Cannabinoid ICSS studies have revealed mixed observations. Particularly,
some studies reveal that low doses of THC can decrease thresholds for ICSS (Gardner et al.,
1988) but others failed to observe facilitation of ICSS with THC (Vlachou et al., 2007;
Wiebelhaus et al., 2015). The differences among the studies could be due to the dose, strain of
animal, or procedural variations. One example is that high, but not lower doses of cannabinoids
are reported to produce anxiogenic effects in mice (Kinden and Zhang, 2015).
The conditioned place preference paradigm is based on the principles of Pavlovian
conditioning. This assay involves three phases (habituation, conditioning and testing) in which
laboratory subjects are tested in an apparatus with two compartments, where one compartment
may contain different floors, environmental and drug-related cues. The other compartment is
paired with the drugs vehicle. During the habituation phase, subjects are allowed to explore
freely the apparatus before conditioning. During the conditioning phase, an unconditioned
stimulus (i.e. drug) is administered to the subject and the animal can explore only one
compartment. Sometimes a 3rd neutral chamber is used but is not paired with a drug, and the
entrance between both compartments can be opened to allow animal subjects free passage
between both chambers. On test days, animals are not administered drug, and the duration of
time spent in each chamber is scored. Subjects will voluntarily spend more time in the
compartment associated with the drug-related cues, if the drug is rewarding, and the vehicle side
if the drug is aversive, and an approximately equal amount of time if the drug is neutral. In the
CPP paradigm, cannabinoids are reported to produce both conditioned place preference (CPP)
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and conditioned place aversion (CPA) to THC (Parker and Gillies, 1995; McGregor et al., 1996;
Chaperon et al., 1998) (See Table 3). Importantly, in most CPP studies, preference or aversive to
THC and other cannabinoids are mainly attributed to the dose and time between the injection and
the test session. For example, high doses of THC produce CPP in rats if the interval between
injection and testing was 24 h. However, if the interval was 48 h, THC produced CPA at high
doses (Lepore et al., 1995). It could be that 48 h after injection, mice are undergoing withdrawal
and have aversive internal states. In mice, THC induces CPP only when the animals were
previously administered a priming injection of THC 24 h before the first conditioning session
(Valjent and Maldonado, 2000), although in CD1 mice without A2A adenosine receptors
utilizing the same methods (Valjent and Maldonado, 2000) THC produced conditioned place
aversion (Soria et al., 2004). These findings indicate the conditioned place preference paradigm
does not produce consistent findings to make inferences regarding the rewarding effects of
cannabinoids.
In contrast to the above mentioned paradigms, cannabinoids consistently and reliably
serve as discriminative stimuli in two-lever or two-aperture drug discrimination studies (Balster
and Prescott, 1992; Barrett et al., 1995; Wiley et al., 1995; Burkey and Nation, 1997; Järbe et al.,
2001, 2014). Cannabinoids are pharmacologically specific in drug discrimination and only drugs
that stimulate CB1 receptors can fully substitute (produce over 80% of total responses on the
lever paired with the training drug) for the discriminative stimulus effects of THC and other
cannabinoids. Likewise, the pharmacological specificity of drug discrimination is observed with
other classes of drugs (Solinas et al., 2006). Therefore, the drug discrimination paradigm has
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proven over time to be the most reliable pre-clinical assay to investigate the
psychoactive/subjective properties of cannabinoids.
Table 1 Evaluation of self-administration (SA) of cannabinoids in laboratory animals
SA = Self-Administration

Species

Drug

Dose

Rhesus monkeys
Rhesus monkeys
Rhesus monkeys
Rhesus monkeys
Rhesus monkeys
Rhesus monkeys

THC
THC
THC
THC
THC
THC

100–400 µg/kg
25 - 300 µg/kg
100–400 µg/kg
17-100 µg/kg
25 - 300 µg/kg
3-300 µg/kg

I.V.
I.V.

Wistar Rat

THC

7.5-300 µg/kg

I.V.

Rat

THC

6.25 - 50 µg/kg

I.V.

Increase SA

Rhesus monkeys

CP 55, 940

0.3–3 µg/kg

I.V.

No SA

Rhesus monkeys

THC

I.V.

No SA

ICR mice
Squirrel Monkey
Squirrel Monkey
Wistar Rat

Win 55,212-2
THC
Win 55,212-2
Win 55,212-2

I.V.
I.V.
I.V.
I.V.

Increase SA
Increase SA
Increase SA
Increase SA

Martellotta et al., 1998
Tanda et al., 2000
Fattore et al., 2001
Fattore et al., 2001

Wistar Rat

CP 55,940

I.C.V

SA

Braida et al. 2001

Squirrel Monkey
Wistar Rat
Squirrel Monkey

THC
THC
AEA
Methanandam
ide

I.V.
I.C.V
I.V.

Increase SA
Increase SA
Increase SA

Justinova et al., 2003
Braida et al., 2004
Justinova et al. 2005

10 - 40 µg/kg

I.V.

Increase SA

Justinova et al. 2005

12.5 µg/kg

I.C.V

SA

Lecca et al. 2006

Squirrel Monkey
Sprague-Dawley
Rat

Win 55,212-2

10–500 µg/kg
1 - 16 µg/kg
6.25 - 50 µg/kg
0.1 - 1.6
mg/2µ1
2 - 8 mg/kg
0.01-1 µg/kg
40 mg/kg

31

ROA Outcome
No SA
No SA
No SA
No SA
No SA
No SA
Partial selfadmin

Reference
Deneau and S, 1971
Deneau and S, 1971
Kaymakcalan, 1973
Pickens et al., 1973
Harris et al., 1974
Carney et al., 1977
Ree et al., 1978
Takahashi and Singer,
1979
Mansbach and
Nicholson, 1994
Mansbach and
Nicholson, 1994

Lister Hooded
Rat
Lister Hooded
Rat
Squirrel Monkey
Sprague-Dawley
Rat
Long - Evans
rats
Squirrel Monkey

Win 55,212-2

12.5 µg/kg

I.V.

Increase SA

Fadda et al. 2006

Win 55,212-2

12.5 µg/kg

I.V.

SA

Fattore et al. 2007

2 - AG

0.1 - 100 µg/kg

I.V.

Increase SA

2 - AG

25 mg/kg

I.V.

Increase SA

Win 55,212-2

0.1 mg/kg

I.V.

SA

AM404

10 µg/kg

I.V.

SA

Justinova et al. 2011
De Luca MA et al.
2014
Lefever TW et al.
2014
Schindler et al. 2016
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Table 2 Evaluation of intracranial self-stimulation of cannabinoids in laboratory animals

Species

Drug

Dose

ROA

Outcome

Long-Evan
Rat

THC,
nabilone

0.12-10 mg/kg

P.O.

Attenuates ICSS

Lewis rat

THC

1.5 mg/kg

I.P.

Facilitates ICSS

Lewis rat

THC

1 and 1.5 mg/kg

I.P.

Attenuates ICSS

THC

1 mg/kg

I.P.

no effect
Facilitates ICSS

Lepore et al., 1996

CP 55,940
SR141716A
(CB1
antagonist)

10 - 50 µg/kg

I.P.

no effect

Arnold et al., 2001

1 - 10 mg/kg

I.P.

Attenuates ICSS

Deroche-Gamonet
et al., 2001

SpragueDawley Rat

WIN 55,212-2

0.1 – 1 mg/kg

I.P.

Attenuates ICSS

Vlachou et al.,
2003

SpragueDawley Rat

URB-597
(FAAH
inhibitor)
SR141716A

0.3 - 3 mg/kg
0.02 mg/kg

I.P.

Attenuates ICSS

Vlachou et al.,
2006

THC

1 - 2 mg/kg

I.P.

Attenuates ICSS

THC

0.5 - 1 mg/kg

I.P.

no effect

WIN 55,212-2

0.1 - 1 mg/kg

I.P.

Attenuates ICSS

THC

0.1 mg/kg
1 mg/kg

I.P.

Facilitates ICSS
Attenuates ICSS

C57bl/6 mice

THC
JZL184
(MAGL
inhibitor)
PF3845
(FAAH
inhibitor)
SA-57

5.6 - 10 mg/kg
16 - 40 mg/kg
30 mg/kg
3 - 17.8 mg/kg

N/A

Attenuates ICSS

Wiebelhaus et al.,
2015

C57bl/6 mice

CP 55,940

0.12 - 0.18
mg/kg

s.c.

Attenuates ICSS

Grim et al., 2015

SpragueDawley rat
Lewis Rat
Lewis rat
SpragueDawley Rat

SpragueDawley Rat
SpragueDawley Rat
SpragueDawley Rat
SpragueDawley Rat
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Reference
Stark and Dews,
1980
Gardner et al.,
1988
Gardner et al.,
1988

Vlachou et al.,
2007
Fokos and
Panagis, 2010
Mavrikaki et al.,
2010
Katsidoni et al.,
2013

Table 3 Evaluation of conditioned place preference (CPP) of cannabinoids in laboratory animals
CPA = conditioned place aversion; CPP = conditioned place preference

Species

Drug

Dose

ROA

Outcome

Reference

THC

1, 2 & 4
mg/kg

I.P.

CPP

Lepore et al, 1995

THC

10 mg/kg

I.P.

CPA

Parker and Gillies, 1995

THC

15 mg/kg

I.P.

CPA

Sañudo-Peña et al.,
1997

Wistar Rat

WIN 55,212-2

1 mg/kg

S.C.

CPA

Chaperon et al., 1998

ICR mice

THC

I.P.

CPA

Wistar Rat

THC

20 mg/kg
1-1.5
mg/kg

I.P.

CPA

Hutcheson et al., 1998
Mallet and Beninger,
1998

Lister
hooded Rat

THC

1.5 mg/kg

I.P.

CPA

ICR mice

THC

5 mg/kg

I.P.

CPA

ICR mice

THC

1 mg/kg

I.P.

CPP

Wistar rat

CP 55, 940

I.P.

CPP

Wistar rat

THC

20 µg/kg
0.075-0.75
mg/kg

Valjent and Maldonado,
2000
Valjent and Maldonado,
2000
Braida et al., 2001

I.P.

CPP

Braida et al., 2004

Rat

AM-404
(endogenous
cannabinoid
reuptake
inhibitor)

1.2510mg/kg

I.P.

CPP

Bortolato et al., 2006

SpragueDawley Rat

THC

0.1 mg/kg

I.P.

CPP

Le Foll et al., 2006

C57bl/6

THC

I.P.

no effect

Vlachou et al., 2007

ICR mice
SpragueDawley Rat
SpragueDawley Rat

THC

I.P.

CPA

Vann et al., 2008

I.P.

no effect

Polissidis et al., 2009

I.P.

CPP

Tampus et al., 2015

LongEvans Rat
SpragueDawley
rats
SpragueDawley Rat

Win 55,212-2
JWH-175

0, 1 & 3
mg/kg
10 mg/kg
0.1-1
mg/kg
0.1 mg/kg
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Cheer et al., 2000

Overview of cannabinoid drug discrimination
In the drug discrimination paradigm, laboratory subjects learn to discriminate a drug from
its vehicle based on Pavlovian and Skinnerian principles of learning. This principle of learning
indicates behavior that is reinforced tends to be repeated and behavior that is not reinforced will
be extinguished. In drug discrimination studies, animal behavior such as nose pokes or lever
presses are reinforced by the presentation of a positive reward (i.e. food pellet). In drug
discrimination procedures, laboratory subjects are trained over time to discriminate the
subjective effects of a drug from its vehicle control. After successful training, subjects will
typically press a lever, or poke their nose in an aperture for reinforcement (i.e. generally food)
inside or on the lever or aperture that is paired with the training drug or its vehicle. After
successful acquisition of a discriminative stimulus, novel drugs can be tested to determine if the
subjective effects of the training drug and the test drug overlap. If responses occur on the same
lever or aperture as the training drug, it is interpreted that the training drug and test drug produce
an overlapping internal stimulus. Usually, test and training drugs will produce overlapping
internal stimuli if both drugs bind the same receptors (Wiley 1999; Solinas et al., 2006).
In contrast, the interpretation of a partially overlapping discriminative stimulus (i.e.
partial substitution) continues to be an ongoing subject of debate in the drug discrimination field
(Solinas et al., 2006). For example, researchers in one lab speculate that partial generalization of
opioids depends on the types of opioid receptors that are activated and the level of intrinsic
activity (Colpaert, 1988). However, if a training drug activates multiple receptors, a test drug that
activates only one of these receptors might be discriminated by some, but not all laboratory

35

subjects. If the data is averaged, it would appear as a partially overlapping discriminative
stimulus, but there might not be any individual subject showing a partial effect (Solinas et al.,
2005). Moreover, another study tested whether adenosine A1 receptor antagonists substitute for
the stimulus effects of caffeine and observed that an A1 antagonist partially overlap with the
caffeine discriminative stimulus and that half of the rats produced all responses on the lever
paired with drug and the other half produce no responses on the aperture paired with drug
(Solinas et al., 2005).
Drugs within the following classification (i.e. nicotinics, hallucinogens, serotonergics,
amphetamine-related

stimulants,

benzodiazepines,

aminotetralines,

MDA,

MDMA,

cannabinoids, opiates, inhalants) serve as reliable discriminative stimuli (Barrett and Appel,
1989; Stolerman and Mariathasan, 2003; Solinas et al., 2004). Amphetamine is thought to act as
an indirect agonist by releasing dopamine and norepinephrine in the brain (Tseng et al., 1976).
Amphetamine serves as a discriminative stimulus and dopaminergic agonists substitute for the
amphetamine discriminative stimulus (Young and Glennon, 1986). Also, cocaine, a
dopaminergic re-uptake inhibitor substitutes for the amphetamine discriminative stimulus
(Goudie, 1991). In addition to stimulants, many drug discrimination studies have been conducted
using the anxiolytics. For example, in rats have been trained to discriminate oxazepam and
diazepam, but the anxiolytic drug buspirone does not substitute in rats trained to discriminate
oxazepam nor diazepam (Hendry et al., 1983). Later, it was discovered that buspirone binds 5HT receptors, which is distinct from benzodiazepines such as oxazepam and diazepam, which
produce their effects on GABA receptors. These observations indicate that laboratory subjects
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can discriminate between drugs from different classes, drugs that produce similar internal states
(i.e. anxiolytic) and between drugs that produce their subjective effects through distinctly
different receptors.
Cannabinoid drug discrimination studies have been conducted for several decades.
Several species of animals have been used to study the subjective effects of cannabinoids in drug
discrimination. Unlike other assays that are used to investigate drug psychoactivity (i.e. CPP,
ICSS, or SA), cannabinoid drug discrimination studies are highly consistent in the observation
that a drug can serve as a discriminative stimulus. In early studies, pigeons were trained to
discriminate THC by pecking a key to receive food reinforcement (Henriksson et al., 1975; Järbe
et al., 1977; Järbe and Hiltunen, 1987). Pigeons are highly sensitive to the subjective effects of
cannabinoids (ability to discriminate low doses), although they are rarely used today in drug
discrimination studies. In pigeons, THC does not substitute for psychomotor stimulants (Järbe,
1982, 1984), which indicates that the subjective effects of psychomotor stimulants are distinctly
different from THC. In rats and mice, different training doses of THC have served as
discriminative stimuli (0.25 - 3 mg/kg) (Henriksson et al., 1975; Järbe and McMillan, 1980).
Also, genetic approaches employing FAAH

(-/-)

mice have become available to understand the

role of FAAH and AEA in the endocannabinoid system (Vann et al., 2009; IgnatowskaJankowska et al., 2015). One very important connection between pre-clinical drug discrimination
and human drug discrimination studies is that pre-clinical studies are a very good predictor of
drug psychoactivity in humans. (Jones and Stone, 1970; Waskow et al., 1970; Fabian et al.,
1983; Chait et al., 1988). This highlights a major advantage of the drug discrimination paradigm,
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which is the high degree of sensitivity, specificity, and cross-species consistencies in the
subjective effects of drugs, in particular, cannabinoids.
Currently, there are no examples that the discriminative stimulus effects of a test drug can
completely substitute for the discriminative stimulus effects of THC without activating central
CB1 receptors. For example, rimonabant blocks the discriminative stimulus effects of THC and
synthetic cannabinoids, but not SR140098, a CB1 antagonist that does not cross the blood-brain
barrier. However, anti-psychotic drugs (i.e. clozapine, haloperidol, thioridazine, and
chlorpromazine) produce all four measures assessed in the tetrad asssay (i.e. catalepsy,
antinociception, hypothermia, hypolocomotion) which is a highly predictive assay to screen for
CB1 receptor activity (Wiley, 2003). These observations of cannabinoids in both the drug
discrimination and tetrad assay indicate that drug discrimination paradigm is the more
pharmacological and behaviorally selective assay for screening the cannabimimetic effects of
drugs. Early THC discrimination studies reported cannabidiol, a non-psychoactive cannabinoid,
did not substitute for the discriminative stimulus effects of THC (Järbe, 1989; Balster and
Prescott, 1992). In addition, drugs that are not considered cannabinoids (i.e. ketamine, alcohol, or
cocaine) did not substitute for THC in mice even at very high doses (McMahon et al., 2008).
However, several studies observed that diazepam, a benzodiazepine, which does not bind CB1
receptors, produces average responses that are consistently above 40% for the aperture/lever
paired with THC (Mokler et al., 1986; Balster and Prescott, 1992; Wiley and Martin, 1999). CB1
receptors are located on glutamatergic neurons, and activating CB1 receptors on glutamatergic
neurons can reduce neuronal activity, and may explain these findings, further highlighting the
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high degree of sensitivity and selectivity of drug discrimination. Interestingly, CB1 receptors do
not contribute to the partial substitution of diazepam for THC because this effect is attenuated by
the benzodiazepine antagonist flumazenil, and not by the CB1 receptor antagonist rimonabant
(Wiley and Martin, 1999).
Finally, cross-substitution of drugs is an important concept in cannabinoid discrimination
because it occurs within drugs of the same class, and through a shared mechanism of action. In
combination with receptor antagonist studies, cross-substitution studies can provide strong
evidence supporting the involvement of a specific receptor mechanism of action of a
discriminative stimulus. Cross substitution is observed among many different cannabinoids
(Barrett et al., 1995). For example, FAAH

(-/-)

and AEA fully substitutes for THC in FAAH
(+/+)

mice have been trained to discriminate Δ9-THC,

(-/-)

. However, AEA is rapidly degraded in FAAH

mice and dose not substitute for THC, suggesting that in the presence of FAAH, AEA cannot

produce similar subjective effects as THC. Previous studies have shown that synthetic
cannabinoids such as CP 55, 940 and WIN 55,212-2 dose-dependently substitute for THC and
cross-substitutes for THC (Wiley, 1999; McMahon et al., 2008). In addition, the synthetic
cannabinoid JWH-018 serves as a discriminative stimulus in rhesus monkeys (Ginsburg et al.,
2012). THC and JWH-073 substitutes for JWH-018, but GABA receptor agonists such as the
benzodiazepines do not substitute for JWH-018 (Rodriguez and McMahon, 2014). One
important observation is that when two different drugs fully substitute for each other (cross
substitution), it usually occurs through the same receptor mechanism of action. In one reported,
mice were trained to discriminate a high dose of methanandamide (70 mg/kg), a drug known to
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bind several receptors (i.e. TRPV1, PPAR α) in addition to the CB1 receptor. In mice trained to
discriminate methanandamide (70 mg/kg) the discriminative stimulus was partially attenuated
(60% mAEA-like responses) by a large dose of rimonabant (30 mg/kg) (Wiley et al., 2011).
Also, a high dose of THC (60 mg/kg) approached full substitution (70% THC-like responses) in
mice trained to discriminate methanandamide (70 mg/kg). The results from this set of
experiments (Wiley et al., 2011) indicate that higher doses of THC and mAEA have similar but
not completely overlapping subjective effects. Given the results in this study, it is plausible that
higher doses of mAEA can produce subjective effects through multiple receptors (i.e. CB1,
TRPV1) and the subjective effects of THC are produced through only one receptor (i.e. CB1).
Because cross substitution was not observed at higher doses (only partial substitution), these
findings validate the idea that cross substitution usually occurs if the mechanism that produces
the subjective effects of two different drugs are exactly the same.

Discriminative Stimulus Properties of Cannabinoid Antagonists
The synthesis of the first antagonist of the CB1 receptor (rimonabant) allowed
investigators to determine the role of this receptor in cannabinoid discrimination (RinaldiCarmona, 1994). Rimonabant attenuates the discriminative stimulus effects of THC in pigeons,
rats, and mice (Wiley et al., 1995; Mansbach et al., 1996; Pério et al., 1996). Antagonist studies
in combination with cross-substitution observations with other cannabinoids provide strong
evidence that CB1 receptors are largely responsible for cannabinoid discrimination.
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Early reports found that rimonabant fails to serve as a discriminative stimulus using food
as a reinforcer (Pério et al., 1996). Interestingly, Rhesus monkeys can learn to discriminate
rimonabant if given chronic administration of THC before training sessions (Stewart and
Mcmahon, 2010), and discontinuation of chronic THC results in a higher number of responses on
the rimonabant associated lever (Stewart and Mcmahon, 2010). Pre-treatment with THC, AEA,
CP 55, 940 or WIN 55, 212-2 before rimonabant on test sessions resulted in responses on the
vehicle-paired lever and not the rimonabant paired lever, suggesting these other cannabinoids
replace the internal subjective effects produced in the absence of chronically administered THC
(Stewart and Mcmahon, 2010). Interestingly, the CB1 antagonist AM251 substituted for
discriminative stimulus effects of rimonabant (McMahon, 2006). The above findings may
indicate CB1 antagonists on their own do not produce subjective effects, but they may induce an
internal state of withdrawal, that may serve as a discriminative stimulus. Additionally, it is
possible that CB1 antagonist produces a non-drug state.

Discriminative Stimulus Properties of Phytocannabinoids
The most commonly investigated cannabinoids in marijuana (i.e. phytocannabinoids) are
THC, cannabidiol (CBD) (Michoulam and Shvo, 1963) cannabinol (CBN) (Wood et al., 1899)
cannabichromene (CBC) (Gaoni and Mechoulam, 1966), Δ9-tetrahydrocannabivarin (THCV)
(Merkus, 1971). THC and CBN are the only phytocannabinoids in marijuana that are reported to
substitute for the discriminative stimulus effects of THC (Browne and Weissman; Järbe and
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Hiltunen, 1987). However, some reports suggest the non-psychoactive cannabinoid CBD can
inhibit the discriminative stimulus effects of THC (Pertwee, 2008; Vann et al., 2008).
THC discrimination was used in early studies to screen for THC-like subjective effects of
phytocannabinoids (i.e. CBN and CBD), and their metabolites (11-OH-THC; 8ß-OH-∆9-THC;
8α-OH-∆9-THC; 8α,11 di-OH-∆9-THC, and 8ß,11 di-OH-∆9-THC) in several different species
(pigeon, gerbil, rodent, non-human primates, human). CBD is generally thought to have no
psychoactive properties on its own, and does not substitute for the discriminative stimulus effects
of THC (Järbe and Hiltunen, 1987; Vann et al., 2008). In addition, drug discrimination was used
to investigate the subjective effects of inhaled marijuana (Marshell et al., 2014b). When
marijuana is inhaled, many constituents (i.e. phytocannabinoids) can interact and different
studies have investigated the discriminative stimulus effects of interacting phytocannabinoids.
Cannabinoid drug discrimination can also been used to rank order the potency of the subjective
effects of phytocannabinoids, and indicates the CBN stimulus is less potent than THC, but the
combination of CBN and THC increases the percentage of responses for THC (Järbe and
Hiltunen, 1987; Järbe et al., 2014). Thus, THC discrimination has been a very useful to
investigate the phytocannabinoids in marijuana that may contribute to the subjective effects of
smoked marijuana.
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Discriminative Stimulus Properties of Endogenous Cannabinoids
Our understanding of the discriminative stimulus properties of endocannabinoids
cannabinoids has been limited until recently because endocannabinoids are rapidly degraded by
FAAH and MAGL. Accordingly, early attempts to discover if the subjective effects of AEA
overlapped with THC were limited in success (Deutsch and Chin, 1993). In one study,
intraperitoneal injections of AEA substituted for the discriminative stimulus effects of THC and
CP 55,940 in rats, but not mice, and only at doses that drastically suppressed response rates
(Wiley et al., 1995; Wiley et al., 2014), indicating the rapid hydrolysis of AEA prevented an
overlapping stimulus in both species.
The synthesis of metabolically stable AEA analogues presented an opportunity to
overcome the challenge of rapid degradation. Although, AEA analogues are distinctly different
molecules from endogenous (AEA), they have some similarities in their structure. Methylations
at carbon 1 and 2 on AEA prevent degradation without significant alterations in affinity or
behavioral activity (Adams et al., 1995). For example, (R)-methanandamide, a metabolically
stable analogue of AEA dose-dependently substituted for the THC (2 mg/kg) discriminative
stimulus in rats (Burkey and Nation, 1997). Interestingly, (R)-methanandamide only produces
full substitution in rats that discriminate lower dose of THC (≤ 3.0 mg/kg) (Järbe et al., 1998).
(R)-methanandamide substituted partially or not at all in rats trained to discriminate 5.6 or 30
mg/kg THC (Järbe et al., 1998, 2000; Wiley et al., 2011). Although methanandamide is
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considered a cannabinoid (Ki = 28.3 ± 3) (Goutopoulos et al., 2001), it also binds TRPV1
receptors that are involved in anandamide-induced reductions in locomotion (de Lago et al.,
2004). This observation offers the possibility that methanandamide produces a discriminative
stimulus at higher doses that could be mediated by TRPV1 receptors, and lower doses is
mediated by CB1 receptors. These findings indicate that lower doses of THC that produce
weaker subjective effects can generate overlaping with the subjective effects with (R)methanandamide. It is possible that (R)-methanandamide is less potent than THC, or is
metabolized before it can occupy the same number of CB1 receptors. Also, THC is more potent
than both O-1812 and 2-methylarachidonyl-2’-fluoroethylamide (analogues of AEA) in mice
trained to discriminate O-1812, and substitutes for THC to a greater degree than exogenous AEA
in rats and monkeys (Wiley et al., 1997, 2004). These observations indicate differences in the
intrinsic activity between various AEA analogues and THC, or that their discriminative stimulus
effects occur through a separate receptor mechanism. More illuminating, the CB1 receptor
antagonist rimonabant (0.3 and 1 mg/kg) completely attenuates the ability of (R)methanandamide (doses ≤ 30 mg/kg) to occasion the lever paired with THC in rats (Järbe et al.,
2001). However, extremely high doses of methanandamide (≥ 70 mg/kg) failed to substitute in
mice trained to discriminate a high dose of THC (30 mg/kg), and rimonabant did not block the
generalization of methanandamide in mice trained to discriminate a high dose of
methanandamide (70 mg/kg). This raises the possibility that a non-CB1 receptor mechanism
generates the discriminative stimulus effects of methanandamide (70 mg/kg) (Wiley et al.,
2011).
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Although short half-lives of the endocannabinoids make it difficult to investigate their
effects, FAAH and MAGL inhibitors preventing the rapid hydrolysis of AEA and 2-AG, provide
tools to prevent their rapid hydrolysis and understand their general pharmacological properties.
Complete blockade of FAAH produces large increases of AEA in mouse brain (Fegley et al.,
2005; Ahn et al., 2009; Long et al., 2009; Niphakis et al., 2012). Exogenous administration of
AEA does not undergo rapid hydrolysis after FAAH inhibition and produces physiological
effects. For example, the FAAH inhibitor URB597 (0.3 mg/kg) or AEA (10 mg/kg) alone does
not substitute for THC in Sprague-Dawley rats, however, co-administration of URB597 and i.v.
AEA (3 mg/kg) completely substitutes for THC (Solinas et al., 2007). These findings suggest
that low doses of exogenously administered AEA are sufficient to produce a THC-like
discriminative stimulus if its primary hydrolytic enzyme is inhibited. Moreover, FAAH (-/-) mice
successfully learn to discriminate both AEA and THC, and cross-substitution occurs with THC
and AEA in FAAH

(-/-)

mice, indicating in the absence of FAAH, AEA can produce internal

subjective states that are similar to THC (Walentiny et al., 2011). The cross-substitution of THC
and AEA in FAAH

(-/-)

mice was attenuated by the CB1 receptor antagonist rimonabant,

indicating a shared contribution of CB1 receptors in the AEA and THC discriminative stimulus
(Walentiny et al., 2011, 2015).
Most drug discrimination research with endocannabinoids has focused on AEA instead of
2-AG. There is one study (Wiley, et al., 2014) in which 2-AG was evaluated in mice trained to
discriminate THC and 2-AG did not substitute for THC (Matuszak et al., 2009). Genetically
modified mice, specifically MAGL(-/-) mice have not been evaluated in a drug discrimination

45

procedure, but several pharmacological inhibitors of MAGL activity have been investigated. The
MAGL inhibitor JZL184 partially substitutes for THC in wild-type mice, and rats trained to
discriminate THC from vehicle (Long et al., 2009; Walentiny et al., 2015). However, one report
indicates JZL184 produced responses on the lever paired with vehicle in mice trained to
discriminate THC (Hruba et al., 2015). Regardless, MAGL inhibition does not produce an
overlaping discriminative stimulus with THC.
Simultaneous blockade of FAAH and MAGL can be obtained by several approaches
which include administering mice the dual FAAH and MAGL inhibitors JZL195 or SA-57 (Long
et al., 2009; Niphakis et al., 2012; Hruba et al., 2015), and co-administering mice selective
FAAH and MAGL inhibitors (Long et al., 2009; Ghosh et al., 2015), or administering MAGL
inhibitors in FAAH(-/-) mice (Long et al., 2009). Dual inhibition produces robust cannabimimetic
effects including antinociception, hypomotility, hyper-reflexia, catalepsy (Long et al., 2009), and
a completely overlapping THC-like discriminative stimulus that are mediate by CB1 receptors
(Long et al., 2009; Hruba et al., 2015). The analgesic effects of dual inhibition are greater than
the effects generated by single enzyme inhibition, and catalepsy is only observed after inhibiting
both enzymes.
Taken together, these observations indicate the discriminative stimulus/subjective effects
of AEA in the presence of FAAH can partially overlap with THC, or completely overlap with
THC in the absence of FAAH. Additionally, inhibiting 2-AG degradation can produce increase
responses for lever/aperture paired with THC. These observations could be due to 2-AG acting
as a full CB1 agonist, while AEA acts as a partial CB1 agonist (Sugiura et al., 2002) indicating 2-
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AG produces greater intrinsic effects at CB1 receptors than AEA. Elevated levels of 2-AG may
achieve greater occupancy of CB1 receptors in the brain than AEA because bulk brain levels of
2-AG are approximately three orders of magnitude higher than AEA (Ahn et al., 2009; Long et
al., 2009).

Table 4 Evaluation of discriminative stimulus properties of cannabinoids in laboratory animals
Species

Training
Drug

Training
Dose

Substitution
Drug

ROA

Outcome

Response
rates

Reference

Pigeon

THC

.15 - .20
mg/kg

THC

I.M.

Complete
Generalizati
on

Decrease

(Henriksson
et al., 1975)

THC

Rats = 3
mg/kg
Pigeon =
1 mg/kg

SP-111
11-OH-Δ9THC
11-OH-Δ8THC

I.M. =
90 min
I.P. =
30 min

Complete
Generalizati
on

Decrease

(Järbe and
McMillan,
1980)

I.P. in
rats
I.M. in
Monke
y

Generalizati
on
More potent
than THC

Decrease

Gold et al.,
1992

I.P.

Complete
Generalizati
on

Decrease

Wiley et al.,
1993

I.P.

Complete
Substitution
Complete
substitution

Decrease

Wiley et al.,
1995

Sprague
Dawley
Rat/Pigeo
n
SpragueDawley
Rat
Rhesus
Monkey
SpragueDawley
Rat
Rhesus
Monkey
SpragueDawley
Rat

THC

3 mg/kg

THC
CP 55,940

THC

3 mg/kg
1 mg/kg

THC
THC

CP
55,940

0.1
mg/kg

THC
WIN 55,212-2
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SpragueDawley
Rat

WIN
55,212-2

SpragueDawley
Rat

RMethana
ndamide
(AEA
analogue)
THC

10 mg/kg
3 mg/kg

SR141716A
Anandamide

Wistar Rat

CP
55,940

0.03 0.014
mg/kg

THC
Rimonabant

3.2
mg/kg

Anandamide
RMethanandami
de

SpragueDawley
Rat

THC

0.3
mg/kg

CP 55,940
THC
Rimonabant

S.C.

Complete
Substitution
Complete
Substitution
Complete
Antagonism

I.P.

Complete
Antagonism
Complete
Substitution

Decrease

Järbe et al.,
2001

I.P.

Complete
Substitution
Complete
Antagonism

No effect

De Vry and
Jentzsch,
2003

I.P.

Partial
Substitution
Complete
Substitution

Decrease

Alici and
Appel, 2004

I.P.

Potentiate
Generalizati
on of THC
Complete
Attenuation

Decrease

Solinas et al.,
2004

Decrease

Wiley et al.,
2004

No effect

Järbe et al.,
2006

SpragueDawley
Rat

THC

3 - 10
mg/kg

B - endorphin
SR141716A

SpragueDawley
Rat

THC
O-1812
(CB1
agonist)

3 mg/kg
0.3
mg/kg

O-1812
THC

I.P.

Complete
Substitution
Complete
Substitution

SpragueDaley Rat

THC
RMethana
ndamide

1.8 - 5.6
mg/kg
10
mg/kg

Rimonabant
AM251

I.P.

Complete
Antagonism
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Pério et al.,
1996

Rhesus
Monkey

Rhesus
Monkey

SpragueDawley
Rat

SpragueDawley
Rat

THC

THC

THC

AM1346
(AEA
analogue)

I.V.

Complete
Antagonism

Statistics
not
reported

McMahon,
2006

0.1
mg/kg

CP 55,940
WIN 55,212-2
RMethanandami
de
Rimonabant

I.V.

Complete
substitution
Complete
substitution
Complete
substitution
Complete
Antagonism

Decrease

McMahon,
2006

3 mg/kg

I.V.Anandamid
e I.V.
Anandamide +
URB597

I.V.

Complete
substitution

Decrease

Solinas et al.,
2007

I.P.

Complete
substitution
Complete
substitution
Complete
substitution

AM1346
= no
change
mAEA =
decrease

Järbe et al.,
2009

JWH-205
= decrease
THC =
decrease

Vann et al.,
2009

Statistics
not
reported

Long et al.,
2009

0.32
mg/kg

3 mg/kg

Rimonabant
AM251

AM1346
mAEA

C57BL/6
mice

THC

10 mg/kg

JWH-202
JWH-204
JWH-205

C57BL/6
mice

THC

5.6
mg/kg

THC
JZL195
JZL184
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S.C.

I.P.

No
substitution
Complete
substitution
Complete
substitution
Complete
Generalizati
on
Complete
substitution
Partial
substitution

FAAH (-/)
mice

SpragueDawley
Rat
SpragueDawley
Rat

THC

5.6
mg/kg

THC
JZL195
JZL184

I.P.

Complete
Generalizati
on
Complete
substitution
Complete
substitution

THC

1.8
mg/kg

WIN 55,212-2

I.P.

Complete
substitution

Statistics
not
reported

Järbe et al.,
2010

10 mg/kg

mAEA
THC

I.P.

Complete
substitution
Complete
substitution

Statistics
not
reported

Järbe et al.,
2010

6 mg/kg

THC

I.P.

Complete
substitution

Decrease

Walentiny et
al., 2011

Decrease

Wiley et al.,
2011

Decrease

Wiley et al.,
2011

Statistics
not
reported

Järbe et al.,
2011

mAEA

FAAH (-/- Anandam
)
mice
ide

C57BL/6
mice

C57BL/6
mice
SpragueDawley
Rat

THC

methanan
damide

THC

30 mg/kg

AEA
methanandami
de
THC
CP 55,940

I.P.

70
mg/kg

methanandami
de
THC

I.P.

3 mg/kg

AM598
AM678
AM2233
WIN55212-2
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I.P.

No
substitution
No
substitution
Complete
substitution
Complete
substitution
Complete
Generalizati
on
No
substitution
Complete
substitution
Complete
substitution

Statistics
not
reported

Long et al.,
2009

Rhesus
Monkey

THC

0.1
mg/kg

0.18
mg/kg
and
0.56
mg/kg
5.6
mg/kg

JWH-018
JWH-073

I.V.

Complete
substitution

Statistics
not
reported

Ginsburg et
al., 2012

THC
AM5983

I.P.

Complete
substitution

Statistics
not
reported

Järbe et al.,
2012

UR-144
XLR-11

I.P.

Complete
substitution

Decrease

Wiley et al.,
2013

SpragueDawley
Rat

AM2389
(CB1
agonist)

C57BL/6
mice

THC

C57BL/6
mice

THC

5.6
mg/kg

KML29

S.C.

No
substitution

No effect

IgnatowskaJankowska et
al., 2014

C57BL/6
mice
FAAH (-/-)
mice

THC
AEA

5.6
mg/kg
6 mg/kg

Org27569 +
Veh Org27569
+ AEA

I.P.

No
substitution

No effect

Gamage et
al., 2014

I.P.

Complete
substitution
Complete
substitution

Decrease

Wiley et al.,
2014

SpragueDawley
Rat

3 mg/kg
THC
0.3
JWH-018
mg/kg

JWH-018
THC
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SpragueDawley
Rat

THC

3 mg/kg

JWH-018
JWH-073
JWH-200
JWH-203
JWH-250
AM-2201 CP
47,497

C57BL/6
mice

THC

5.6
mg/kg

JZL184 + PF3845
SA57
JZL195

C57BL/6
mice

CP
55,940

0.1
mg/kg

MJN110
JZL184

C57BL/6
mice

CP
55,940
AEA

0.1
mg/kg
6 mg/kg

ZCZ-011 + CP
55,940
ZCZ-011 +
AEA
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I.P.

Complete
substitution
Complete
substitution
Complete
substitution
Complete
substitution
Complete
substitution
Complete
substitution

JWH-073
=
Decrease
CP 47,497
=
Decrease

Gatch and
Forster, 2014

I.P.

Complete
substitution
Complete
substitution
Complete
substitution

Statistics
not
reported

Hruba et al.,
2015

I.P.

Complete
substitution
Complete
substitution

IgnatowskaMJN110 =
Jankowska et
increase
al., 2015

I.P.

Augments
substitution

IgnatowskaJankowska et
al., 2015

No effect

SpragueDawley
Rat

THC

3 mg/kg

ADB-PINACA
THJ-2201
RCS-4
JWH-122
JWH-210

SpragueDawley
Rat

THC

3 mg/kg

AM2201
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I.P.

Complete
substitution
Complete
substitution
Complete
substitution
Complete
substitution
Complete
substitution

I.P.

Complete
substitution

JWH-210
= decrease
MDMA =
decrease
RCS-4 =
decrease

Gatch and
Forster, 2016

Statistics
not
reported

Järbe et al.,
2016

Rationale and Hypothesis

Overall Hypothesis
The overall hypothesis of this dissertation is that an inhibitor of the primary
endocannabinoid regulating enzymes FAAH and MAGL will serve as a discriminative stimulus
via a CB1 receptor mechanism of action, and inhibiting both FAAH and MAGL are necessary to
generate the discriminative stimulus.
Selection of SA-57
The dual FAAH-MAGL inhibitor SA-57 was selected as the training drug in this
dissertation research because it is one of two available pharmacological inhibitors (i.e. SA-57,
JZL195) of the endocannabinoid regulating enzymes FAAH and MAGL. SA-57 has the added
benefit over JZL195 because it is more potent for FAAH than MAGL (Niphakis et al., 2012),
which provides a tool to examine the consequences of inhibiting FAAH with varying degrees of
inhibiting MAGL. In addition, SA-57 produces around (10-fold) elevations of AEA and 2-AG in
the brain and inhibits FAAH (IC50 = 1-3 nM) and MAGL (IC50 = 10 µM). At low doses (≤
1mg/kg) SA-57 produces maximum AEA elevation and at higher doses it incrementally elevates
2-AG. This allows us to investigate the dose-related effects of full FAAH inhibition (i.e.,
maximized increases in endogenous AEA levels in brain) combined with incremental increases
of 2-AG.
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Chapter 2. Characterization of the SA-57 discriminative stimulus
To test the hypothesis that the FAAH and MAGL inhibitor SA-57 would serve as a novel
discriminative stimulus, we employed the drug discrimination paradigm. First, we trained
C57BL/6J mice to discriminate CP 55,940, and then FAAH (-/-) mice trained to discriminate AEA
in order to select a training dose of SA-57. Then, we administered SA-57 in a double alternation
schedule to determine if SA-57 could be discriminated from its vehicle. We anticipated SA-57
would serve as a discriminative stimulus because the dual FAAH and MAGL inhibitor JZL195
fully substitutes for THC (Long et al., 2009) and elicits cannabimimetic effects, as assessed in
the tetrad assay (Long et al., 2009; Anderson et al., 2014; Ghosh et al., 2015), as well as
impaired performance in a Morris water maze spatial memory task (Wise et al., 2012). We
continued our characterization of the SA-57 discriminative stimulus by conducting a time course
study. We anticipated maximum responding for SA-57 would occur at approximately 2h, which
corresponds to maximal brain levels of AEA and 2-AG. Finally, we sought to determine if CB1
receptors were required for the SA-57 discriminative stimulus. In order to determine the receptor
mechanism of action, mice were administered the CB1 receptor antagonist rimonabant.
The second major goal of this dissertation was to determine if inhibiting both FAAH and
MAGL in combination, or inhibiting FAAH or MAGL separately was necessary to generate the
SA-57 discriminative stimulus. To test this hypothesis, we investigated each enzyme targets of
SA-57 (FAAH, MAGL, ABHD6) to delineate the contribution of each enzyme.

First we

administered the dual inhibitor, JZL195 to determine if the subjective effects of different dual
FAAH and MAGL inhibitors would overlap. We expected JZL195 to substitute for SA-57
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because both inhibitors completely block FAAH and MAGL activity, and fully elevate AEA and
2-AG. Next we administered two selective FAAH inhibitors (PF3845 and URB597) to test
whether FAAH inhibition alone, would substitute for SA-57. Then, we administered two
selective MAGL inhibitors (JZL184 and MJN110) determine whether MAGL inhibition alone,
would substitute for SA-57. These studies revealed that MAGL inhibitors but not FAAH did in
fact fully substitute for SA-57. Also, we employed rimonabant to determine whether CB1
receptors mediate these effects. Furthermore, we sought to determine if the substitution of
MAGL inhibitors was mediated through CB1 receptors. Finally, because FAAH inhibition
elevates other lipids in addition to AEA (i.e., PEA and OEA) and AEA also binds TRPV1 and
PPARα receptors (Lo Verme et al., 2005) we employed a selective receptor antagonist of each
receptor to investigate their role in the SA-57 discriminative stimulus.
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Chapter 2. Characterization of the SA-57 discriminative stimulus
Introduction
Cannabinoid CB1 (Devane et al., 1988; Matsuda et al., 1990) and CB2 receptors (Munro
et al., 1993) and their endogenous ligands N-arachidonoyl ethanolamine (anandamide; AEA)
(Devane et al., 1992) and 2-arachidonoylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura et
al., 1995) represent primary elements of the endocannabinoid system. This system modulates
many physiological processes, including pain (Hohmann et al., 2005; Kinsey et al., 2010;
Woodhams et al., 2012; Ignatowska-Jankowska et al., 2014), memory (Hampson and
Deadwyler, 1999), appetite (Kirkham and Tucci, 2006), and reward (Tsou et al., 1998;
Marsicano and Lutz, 1999). The primary psychoactive constituent of Cannabis, Δ9tetrahydrocannabinol (THC) (Gaoni and Mechoulam 1964), produces its psychotomimetic
effects through CB1 receptors (Huestis et al., 2001), and induces dopamine release in the nucleus
accumbens (Chen et al., 1991), though to a substantially lower magnitude than other abused
drugs. Curiously, THC produces reinforcing effects in some (Gardner et al., 1988; Lepore et al.,
1996; Justinova et al., 2003, 2005), but not all (Vlachou et al., 2007; Wiebelhaus et al., 2015)
preclinical laboratory animal models. In contrast, THC serves as a reliable discriminative
stimulus in the drug discrimination paradigm (Henriksson et al., 1975; Järbe, 1989; Wiley et al.,
1997; Vann et al., 2009), an assay that is highly predictive of drug psychoactivity in humans
(Chait et al., 1988; Kamien et al., 1993; Lile et al., 2012).
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Whereas THC elicits relatively long-lasting pharmacological effects, AEA and 2-AG
produce short-lived effects because of rapid hydrolysis by their respective primary catabolic
enzymes fatty acid amide hydrolase (FAAH) (Cravatt et al., 1996, 2001) and monoacylglycerol
lipase (MAGL) (Di Marzo et al., 1999; Dinh et al., 2002). Accordingly, inhibitors of these
enzymes elevate endocannabinoid brain levels, and represent useful investigative tools. Although
the selective FAAH inhibitors URB597 (Fu et al., 2005) and PF-3845 (Ahn et al., 2009) elevate
AEA brain levels and produce antinociceptive effects, neither compound substitutes for THC
(Gobbi et al., 2005;Wiley et al., 2014). Similarly, the MAGL inhibitor JZL184 elevates
endogenous 2-AG brain levels and produces antinociception, but only partially substitutes for
THC (Long et al. 2008; Long et al. 2009; Wiley et al. 2014; Walentiny et al. 2015). Conversely,
the dual FAAH-MAGL inhibitor JZL195 fully substitutes for THC, elicits a constellation of
cannabimimetic effects (Long et al., 2009; Wise et al., 2012; Hruba et al., 2015) and produces an
increased magnitude of antinociceptive effects compared with single enzyme inhibition (Long et
al., 2009; Ghosh et al., 2015). Similarly, the dual FAAH-MAGL inhibitor SA-57 fully
substitutes for THC in wild-type mice (Hruba et al. 2015).
As it has yet to be established whether an inhibitor of endocannabinoid hydrolysis can
serve as the training drug in drug discrimination procedures, the present study investigated
whether mice will learn to discriminate SA-57 from vehicle. SA-57 inhibits FAAH much more
potently than it inhibits MAGL or ABHD6, another serine hydrolase that degrades 2-AG, but to
a much less extent than MAGL (Blankman et al., 2007). Thus, SA-57 possesses utility to
investigate the consequences of maximally elevating brain AEA levels, while dose-dependently
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increasing brain 2-AG levels (Niphakis et al., 2012). To select the SA-57 training dose, initial
experiments examined its dose-effect relationship to substitute for the potent CB1 receptor
agonist CP 55,940 in C57BL/6J mice and AEA in FAAH (-/-) mice (to prevent rapid hydrolysis).
Having established that mice learn to discriminate SA-57 from vehicle, we then assessed its
dose-response relationship and time course. Because various substrates of FAAH (e.g., AEA,
palmitoylethanolamide (PEA), and oleoylethanolamide (OEA)) and MAGL (e.g., 2-AG) bind
CB1, CB2, TRPV1(Smart et al., 2000), and peroxisome proliferator-activated receptor-alpha
(PPARα) receptors (Lo Verme et al., 2005), we tested whether antagonists for these receptors
would block the discriminative stimulus effects of SA-57. Additionally, we conducted an
extensive series of drug substitution tests to gain further insight into the training dose of the SA57 discriminative stimulus. Specifically, we tested whether CP 55,940, as well as the noncannabinoid psychoactive drugs nicotine and diazepam would substitute for the SA-57. As
MAGL also plays a rate limiting role in the production of arachidonic acid and prostanoids in
brain (Nomura et al., 2011), we examined whether the COX-2 inhibitor valdecoxib, which
reduces prostanoid synthesis but does not affect brain endocannabinoid levels, would substitute
for SA-57. The final goal of the present study was to elucidate the degree to which relevant
endocannabinoid hydrolytic enzyme inhibitors contribute to the SA-57 training dose.
Accordingly, we investigated whether individual FAAH, MAGL, and ABHD6 inhibitors, we
well as simultaneous inhibition of FAAH and MAGL would substitute for SA-57.
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Materials and methods
Subjects
Male C57BL6/J mice (Jackson Laboratory; Bar Harbor, ME) and male FAAH (-/-) mice
served as subjects. The FAAH (-/-) mice were backcrossed >14 generations on to a C57BL6/J
background. The mice were 9-11 weeks of age at the beginning of training and were individually
housed in a temperature-controlled (20-22°C) vivarium in accordance with Virginia
Commonwealth University Institutional Animal Care and Use Committee guidelines. Mice were
given water ad libitum, and were food restricted to 85-90% of free-feed body weight, which was
established during a two-week period of ad libitum food every six months.

Drugs
SA-57, MJN110, KT182, KT195, and JZL195 were synthesized in the Cravatt laboratory,
as previously described (Long, Nomura, et al., 2009; Niphakis et al., 2012, 2013; Hsu et al.,
2013). N-arachidonoyl ethanolamine (AEA) was provided by Organix Inc. (Woburn, MA), and
valdecoxib was provided by Sigma-Aldrich (Saint Louis, MO). CP 55,940, JZL184, PF-3845,
rimonabant, and SR144528 were generously supplied by the National Institute on Drug Abuse
(NIDA) (Rockville, Maryland, USA). Capsazepine was purchased from Cayman Chemical, and
GW6471 was purchased from Tocris Bioscience. Each compound was dissolved in a vehicle
consisting of ethanol, emulphor-620 (Rhodia, Cranbury, New Jersey, USA), and saline in a ratio
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of 1:1:18. All injections were given via the intraperitoneal (i.p.) route of administration in a
volume of 10 µl per 1 g of body weight.

Apparatus
Drug discrimination was conducted in eight sound-attenuating operant conditioning
boxes (18 x 18 x 18 cm) (MED Associates, St. Albans, VT). Each operant box contained two
nose poke apertures, and a food dispenser delivering 14-mg food pellets to a receptacle chamber
located between apertures. Computer software (MED-PC® IV, MED Associates, St. Albans, VT)
was used to record nose pokes and to control stimulus presentations and food deliveries.

Drug Discrimination Paradigm
Training
Separate groups of mice were trained to discriminate each of the following three training
drugs from vehicle. Groups 1 and 2 consisted of C57BL6/J mice (n=8) trained to discriminate
CP 55,940, and FAAH (-/-) mice (n=11) trained to discriminate AEA, respectively. The third
group of mice consisted of three cohorts of C57BL6/J mice (n=8/cohort) trained to discriminate
SA-57 from vehicle. The treatment conditions for each cohort are described below under
Testing. The pretreatment times for the training drugs were 120 min for SA-57 and 30 min for
CP 55,940 and AEA. During each 15 min training session, both nose poke apertures were
available, but only responses into the correct aperture associated with the appropriate training
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drug or vehicle resulted in food reinforcement. Each incorrect response reset the response
requirement. Injections before training sessions were conducted (Monday-Friday) in a double
alternation sequence of drug (SA-57, CP 55,940, or AEA) and vehicle (e.g., vehicle, vehicle,
drug, drug).

Testing
Test sessions were scheduled twice per week, with a minimum of 72 h between test days.
To be eligible for testing, subjects were required to meet the following three criteria on nine of
the previous ten consecutive training sessions: 1) correct completion of the first FR10 (i.e., first
10 consecutive responses into the appropriate aperture); 2) ≥ 80% correct responding; and 3)
maintain response rates ≥ 10 responses/min. During the 15-min test sessions, responses in either
aperture resulted in the delivery of food reinforcement according to an FR10 schedule of
reinforcement, without a limitation on the number of reinforcers earned within a session. Before
conducting substitution tests, dose-response tests with SA-57, CP 55,940 or AEA were
conducted to characterize their generalization gradients to their respective discriminative
stimulus. For time course studies, animals were injected with SA-57 (10 mg/kg) and tested at
0.25, 1, 2, 4, or 8 h after injection. In order to assess whether CB1 receptors mediated the
discriminative effects of SA-57, and the substitution of CP 55,940, MJN110, JZL184, and
JZL195, we challenged with the CB1 antagonist rimonabant (3 mg/kg; Rinaldi-Carmona, 1994).
We also examined whether the CB2 receptor antagonist SR144528 (3 mg/kg; Rinaldi-Carmona et
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al., 1998), the TRPV1 receptor antagonist capsazepine (5 mg/kg; Kinsey et al. 2009), and the
PPARα receptor antagonist GW6471 (2 mg/kg; Lo Verme et al. 2005) would block the
discriminative stimulus effects of SA-57. Each antagonist was administered 15 min prior to
injections of 10 mg/kg SA-57. The three cohorts of mice trained to discriminate SA-57 were
employed in the following experiments. All cohorts were included in the SA-57 acquisition
curve. Cohort 1 was used in the time-course study, the MJN110 (0.25 – 5 mg/kg), KT182 (1 and
2 mg/kg), KT195 (40 mg/kg), valdecoxib (10 mg/kg), and MJN110 (2.5 mg/kg) + PF3845 (10
mg/kg) substitution studies; cohort 2 was used to test the psychoactive non-cannabinoid drugs
nicotine (1.5 mg/kg) and diazepam (10 mg/kg), and in substitution tests with JZL195 (2-20
mg/kg), JZL184 (4-100 mg/kg), PF3845 (10 and 30 mg/kg), and URB597 (10 mg/kg); and
cohort 3 was used in the receptor antagonist experiments (rimonabant, SR144528, capsazepine,
GW6471).

[3H] SR141716A binding assay
Cerebella were dissected from adult male ICR mice, stored at -80°C, and membranes
were prepared as described previously (Selley et al., 2004). Membrane protein (15 µg) was
incubated with 0.94 nM [3H] SR141716A in assay buffer (50 mM Tris-HCl, pH 7.4, 3 mM
MgCl2 and 0.2 mM EGTA) with 0.5% (wt./vol) bovine serum albumin (BSA) in the presence
and absence of 5 µM unlabeled SR141716A to determine non-specific and specific binding,
respectively. The assay was incubated for 90 min at 30°C and terminated by rapid filtration
under vacuum through Whatman GF/B glass fiber filters that were pre-soaked in Tris buffer
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containing 0.5% (wt./vol) BSA (Tris-BSA), followed by five washes with cold Tris-BSA. Bound
radioactivity was determined by liquid scintillation spectrophotometry at 45% efficiency in
ScintiSafe Econo 1 scintillation fluid after a 12-h delay.

Data analysis
The percentage of drug appropriate responses and response rates (responses/min) were
recorded for each experiment. Full substitution was defined as greater than or equal to 80% nose
pokes that occurred into the aperture associated with the training drug. Partial substitution was
defined as greater than or equal to 20% and less than 80% nose pokes in the training drug-paired
aperture. Less than 20% nose pokes on the drug-paired aperture was defined as no substitution
(Solinas et al., 2006). ED50 values (and 95% confidence intervals) for generalization or
substitution were calculated using least squares linear regression analysis. Behavioral data are
depicted as mean ± S.E.M. The data were analyzed using one-way or two-way ANOVA.
Dunnett's tests or Bonferroni post hoc analyses were used following a significant ANOVA for
the response rate data. GraphPad Prism 6.0 statistical software (Graph Pad Software, Inc., La
Jolla, CA) was used for data analysis.
Binding data were determined in triplicate and are reported as specific binding. Each
competition dataset was analyzed by one-way ANOVA to determine concentration-dependence.
Rimonabant competition curves were analyzed by non-linear regression to determine IC50 and
Hill coefficients using a four parameter fit with GraphPad Prism 6.0. The IC50 values were then
converted to Ki values using the Cheng-Prusoff equation.
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Results
SA-57 substitutes for CP 55,940 in C57BL/6J mice and AEA in FAAH (-/-) mice
Figure 1 shows that SA-57 fully substituted for CP 55,940 and AEA in mice trained to
discriminate each of these drugs. C57BL/6J mice administered either CP 55,940 or SA-57
completely occasioned the discriminative stimulus effects of CP 55,940 (Figure 1A). SA-57 did
not affect response rates; however, CP 55,940 significantly reduced response rates [F (4,55) =
4.7; p < 0.01], with 0.2 mg/kg yielding significant reductions in response rates compared with
vehicle (Figure 1B). In FAAH (-/-) mice trained to discriminate AEA (6 mg/kg) from vehicle,
SA-57 also fully substituted for AEA (Figure 1C). FAAH (-/-) mice administered AEA (1-30
mg/kg) or SA-57 (1-10 mg/kg) dose-dependently selected the aperture associated with AEA
(Figure 1C). Both AEA [F (4, 50) = 27.5; p < 0.001] and SA-57 [F (5, 46) = 15.27; p < 0.001]
significantly reduced response rates (Figure 1D). The highest doses tested of AEA (i.e., 30
mg/kg) and SA-57 (i.e., 17 mg/kg) significantly depressed response rates compared with vehicle
in FAAH (-/-) mice.
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Figure 1. Effects of CP 55,940, AEA and SA-57 on percentage of responses in training drugpaired apertures and response rates in C57BL/6J mice trained to discriminate CP 55,940 (0.1
mg/kg) or FAAH (-/-) mice trained to discriminate AEA (6 mg/kg).
A) Dose-dependent generalization of CP 55,940 and dose-dependent substitution of SA-57 for
the CP 55,940 discriminative stimulus. The respective ED50 (95% CI) values for CP 55,940
generalization and SA-57 substitution in C57BL/6J mice were 0.04 (0.03 - 0.05) mg/kg and 2.4
(1.6 – 3.6) mg/kg. B) Respectively, CP 55,940 (0.2 mg/kg), but not SA-57, significantly
decreased rates of responding compared to vehicle. C) Dose-dependent generalization of AEA
and dose-dependent substitution of SA-57. The respective ED50 (95% CI) values for AEA and
SA-57 in FAAH (-/-) mice were 2.7 (2.3-3.1) mg/kg and 3.1 (2.8-3.4) mg/kg. D) SA-57 (17
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mg/kg) and AEA (30 mg/kg) decreased rates of responding. Values represent mean ± SEM.
Filled symbols indicate significant difference (p < 0.001) vs. vehicle; n = 7-10 mice/group.

The SA-57 discriminative stimulus
Because 10 mg/kg SA-57 fully substituted for CP 55,940 in C57BL/6J mice and for
FAAH (-/-) mice, this dose of SA-57 was selected as the training dose in three naïve cohorts of
mice (n = 8 mice/group). As shown in Figure 2, 50% of mice achieved the criteria to
discriminate SA-57 from vehicle by the 27th training session, and 23 of 24 mice acquired the
discrimination by day 40. The final mouse achieved criteria on day 74 of training, but was
excluded from subsequent experiments because of its substantial delay in acquisition. Similar
rates of acquisition were found for CP 55,940 in C57BL/6J mice and AEA in FAAH (-/-) mice.
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Figure 2. Acquisition rates of SA-57 (10 mg/kg) in C57BL/6J mice, AEA (10 mg/kg) in FAAH
(-/-) mice, and CP 55,940 (0.1 mg/kg) in C57BL/6J mice trained in drug discrimination.
Values represent percentage of mice that achieved criteria (see text) across days. n = 24 mice for
SA57, 12 for AEA, and 12 for CP 55,940.
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Figure 3 shows the time course effects of 10 mg/kg SA-57 vs. vehicle for selecting the
aperture associated with SA-57 (Figure 3A) and response rates (Figure 3B). Whereas mice that
received vehicle responded consistently on the vehicle-associated aperture at each of the time
points, mice administered 10 mg/kg SA-57 selected the SA-57 aperture ≥ 80% at 1 and 2 h post
injection, showed partial substitution at 0.25 and 4 h, and responded predominantly on the
vehicle aperture 8 h after injection. There were no differences in rates of responding between
mice injected with vehicle or SA-57 at any time point (Figure 3B; p = 0.48).

69

Figure 3. Time course effects for occasioning the 10 mg/kg SA-57 training dose.
A) Percentage of responses in the SA-57-associated aperture 0.25, 1, 2, 4, or 8 h following an
injection of vehicle or SA-57 (10 mg/kg). B) SA-57 did not affect response rates at any time
point after administration. Values represent mean ± SEM; n = 7 mice/group.
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As shown in Figure 4, the CB1 receptor antagonist rimonabant (0.03-3 mg/kg), significantly
blocked the SA-57 training dose. In contrast, the CB2 receptor antagonist SR144528 (3 mg/kg),
the TRPV1 receptor antagonist capsazepine (5 mg/kg), and the PPARα receptor antagonist
GW6471 (2 mg/kg) did not block the SA-57 training dose (Table 1).
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Figure 4. CB1 receptors play a necessary role in the SA-57 discriminative stimulus.
A) Rimonabant (0.03-3 mg/kg) significantly attenuated the SA-57 training dose. B) Rimonabant
doses (i.e., 0.1, 0.3, 1, 3 mg/kg) that blocked the SA-57 training dose did not reduce response
rates. Triangles represent vehicle controls, and open circles represent injections of SA-57. Values
represent mean ± SEM; n = 3-6 mice/group.
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Table 1. CB1 receptors mediate the discriminative stimulus effects of the SA-57 (10 mg/kg)
training dose. The CB1 receptor antagonist rimonabant (3 mg/kg) significantly blocked the
discriminative stimulus effects of SA-57 (10 mg/kg) as well as substitution of CP 55,940 (0.1
mg/kg). The CB2 receptor antagonist SR144528 (3 mg/kg), the TRPV1 receptor antagonist
capsazepine (5 mg/kg), and the PPARα receptor antagonist GW6471 (2 mg/kg) did not block the
SA-57 (10 mg/kg) discriminative stimulus. The vehicle-vehicle and rimonabant-vehicle
conditions are the same as those used in Figure 9. Values represent mean ± SEM. n = 6-8
mice/group.
% SA-57 Substitution +/Drug

Vehicle

SA-57

Antagonist

SEM

Nose Pokes/min +/- SEM

Vehicle

12.8 ± 9.4

38.9 ± 3

Rimonabant

4.0 ± 1.2

24.9 ± 3

SR144528

0.7 ± 0.3

36.6 ± 3.8

Capsazepine

1.3 ± 0.4

20.1 ± 2.6

GW6471

0.3 ± 2.6

24.6 ± 3.1

Vehicle

95.7 ± 1.7

27.3 ± 1.9

Rimonabant

3.4 ± 1.2

20.1 ± 2.5

SR144528

98 ± 1.5

30.5 ± 5.4

Capsazepine

86 ± 12.2

15.7 ± 2.9

GW6471

96.5 ± 1.3

19.0 ± 2

Vehicle

82.5 ± 11

33.1 ± 3.3

Rimonabant

10.4 ± 5.7
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20.7 ± 4.9

CP 55,940

SA-57 does not bind CB1 receptors
As the SA-57 discriminative stimulus required CB1 receptor activation, we next
examined whether this compound interacts directly with CB1 receptors. Accordingly, we tested if
SA-57 would displace [3H] SR141716A binding in mouse cerebellar membranes. As shown in
Figure 5, rimonabant (i.e., unlabeled SR141716A) inhibited [3H] SR141716A binding in a
concentration-dependent manner (p < 0.001, F = 17.36, df = 7), with a Ki value of 0.75 ± 0.16
nM and Hill coefficient of 0.97 ± 0.08. In contrast, SA-57 (0.01 to 10 µM) did not inhibit [3H]
SR141716A binding (p = 0.96; Figure 5), indicating that this compound does not directly interact
with CB1 receptors.
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Figure 5. SA-57 does not compete with [3H] SR141716A binding to CB1 receptors in mouse
cerebellum.
Data represent mean [3H] SR141716A bound (pmol/mg) ± SEM in the presence of varying
concentrations of rimonabant or SA-57 (n = 3). Specific binding of [3H] SR141716A in the
absence of competing ligand was 1.65 ± 0.26 pmol/mg. Similar results were obtained with [3H]
CP 55,940 binding in membranes prepared from Chinese hamster ovary cells stably expressing
the mouse CB1 receptor, in which concentrations of up to 10 µM SA-57 did not affect binding
(data not shown).
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Substitution tests in SA-57 discriminating mice
We next tested whether the non-cannabinoid, psychoactive compounds, nicotine and
diazepam, would substitute for SA-57. As shown in Figure 6A, nicotine did not substitute for
SA-57, but diazepam produced partial substitution. Both drugs significantly reduced response
rates [Figure 6B; F (3,28) = 14.01; p < 0.001], demonstrating that behaviorally active doses were
reached.
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Figure 6. Substitution experiments of non-cannabinoid psychoactive drugs nicotine (1.5 mg/kg)
and diazepam (10 mg/kg) for the SA-57 training dose.
A) Nicotine did not substitute, while diazepam partially substituted for the SA-57 training dose.
B) Nicotine (1.5 mg/kg) and diazepam (10 mg/kg) significantly reduced rates of responding.
Values represent mean ± SEM. Asterisks indicate significant difference (p < 0.05) vs. vehicle; n
= 7-8 mice/group.
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Figure 7 shows the dose-effect curves of the mixed CB1/CB2 receptor agonist CP 55,940,
the dual FAAH-MAGL inhibitor JZL195, and SA-57 in mice trained to discriminate SA-57 (10
mg/kg) from vehicle. CP 55,940, JZL195, and SA-57 produced dose-related responding into the
aperture associated with SA-57 (Figure 7A). CP 55,940 [F (3,28) = 2.99, p < 0.05] and SA-57 [F
(4,42) = 2.78, p < 0.05], but not JZL195, reduced response rates (Figure 7B).
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Figure 7. Evaluation of the dose-response relationships of SA-57, CP 55,940, and JZL195 to
occasion the SA-57 (10 mg/kg) discriminative stimulus.
A) SA-57 produced dose-dependent generalization, and CP 55,940 and JZL195 dosedependently substituted for SA-57. The respective ED50 (95% CI) values for CP 55,940
substitution, JZL195, and SA-57 generalization were 0.096 (0.076 – 0.121) mg/kg, 6.2 (3.5 –
10.9) mg/kg, and 4.4 (3.5 - 5.4) mg/kg. B) Respectively, doses of CP 55,940 (0.2 mg/kg) or SA57 (17 mg/kg) significantly reduced response rates. Values represent mean ± SEM. Filled
symbols indicate significant difference (p < 0.05) vs. vehicle; n = 7-8 mice/group.
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SA-57 generalized to itself in a dose-dependent fashion, and the MAGL inhibitors
MJN110 and JZL184 dose-dependently substituted for SA-57 (Figure 8A). Although MJN110
did not affect response rates [F (6, 48) = 0.33, p = 0.92], the highest doses of SA-57 (17 mg/kg)
[F (5, 42) = 3.391, p < 0.05] and JZL184 (100 mg/kg) [F (4, 18) = 3.985, p < 0.05] significantly
reduced response rates (Figure 8B).
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Figure 8. Evaluation of the dose-response relationships of SA-57, MJN110 and JZL184 to
occasion the SA-57 (10 mg/kg) stimulus.
A) Dose-dependent generalization of SA-57 and dose-dependent substitution of MJN110 and
JZL184. The respective ED50 (95% CI) values for MJN110 and JZL184 generalization and SA57 substitution in C57BL/6J mice were 0.77 (0.53 – 1.1) mg/kg and 20.44 (11 – 37.97) mg/kg,
and 4.39 (3.53 – 5.45) mg/kg. B) SA-57 (17 mg/kg) and JZL184 (100 mg/kg), significantly
decreased rates of responding. Values represent mean ± SEM. ** indicate significant difference
(p < 0.001) vs. vehicle; n = 7-8 mice/group.
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As shown in Figure 9A, rimonabant (3 mg/kg) completely blocked substitution of
MJN110 (5 mg/kg), JZL184 (100 mg/kg), and JZL195 (20 mg/kg) for the SA-57 training dose.
Also, rimonabant significantly reduced rates of responding [Figure 9B; F (1, 29) = 11.91, p <
0.01].
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Figure 9. Substitution of MJN110 (5 mg/kg), JZL184 (100 mg/kg) and JZL195 (20 mg/kg) for
SA-57 (10 mg/kg) requires CB1 receptors.
A) Rimonabant (3 mg/kg) completely blocked MJN110, JZL184 and JZL195 substitution. B)
Rimonabant did affect response rates. Values represent mean ± SEM; n = 7-8 mice/group.
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In contrast, mice administered high doses of the FAAH inhibitors PF-3845 (10 and 30
mg/kg) and URB597 (10 mg/kg) selected the vehicle aperture (Table 5). Likewise, mice given
dosesABHD6 inhibitors that completely block enzyme activity, KT182 (1 and 2 mg/kg) or
KT195 (40 mg/kg), as well as mice given high dose of the selective COX2 inhibitor valdecoxib
(10 mg/kg) selected the vehicle aperture.
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Enzyme

Drug (mg/kg)

% SA-57 Substitution +/- SEM

(Nose Pokes/min) +/-SEM

Vehicle

0.6 ± 0.5

47.5 ± 4.9

PF-3845 (10)

1.5 ± 0.5

34.4 ± 3.8

PF-3845 (30)

0.7 ± 0.2

38.9 ± 3.5

URB597 (10)

2.1 ± 1.0

36.9 ± 5.6

Vehicle

1.1 ± 0.6

46.5 ± 2.6

KT182 (1)

1.4 ± 0.7

41.1 ± 3.5

KT182 (2)

1.4 ± 0.8

43.5 ± 2.4

KT195 (40)

0.8 ± 0.3

38.1 ± 3.1

Vehicle

1.1 ± 0.6

46.5 ± 2.6

Valdecoxib (10)

1.1 ± 0.7

31.9 ± 3.9

FAAH

ABHD6

COX2

Table 5. FAAH inhibitors (PF-3845 and URB597), ABHD6 inhibitors (KT182 and KT195), and
the COX2 selective inhibitor valdecoxib do not substitute for the discriminative stimulus effects
of SA-57 (10 mg/kg) in C57BL/6J mice and do not affect response rates. Values represent mean
± SEM; n = 7-8 mice/group.
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Because MAGL inhibitors, but not FAAH inhibitors, substituted for SA-57, we next
examined whether full FAAH inhibition would elicit a leftward shift in the MAGL substitution
dose-response curve. Accordingly, we tested the dose-response relationship of MJN110 with
PF3845 (10 mg/kg) or vehicle for substitution in mice trained to discriminate SA-57 from
vehicle. As shown in Figure 10A, PF-3845 elicited a significant leftward shift in the MJN110
substitution dose-response curve [potency ratio (95% CL) = 1.84 (1.3 – 2.8)] (Colquhoun, 1971).
The ED50 (95% CI) values for the MJN110 + Veh and MJN110 + PF3845 groups were 0.89
(0.68 – 1.15) and 0.51 (0.27 – 0.95) mg/kg, respectively. No significant changes were found for
response rates (Figure 10B).
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Figure 10. The FAAH inhibitor PF-3845 augments the MJN110 substitution dose-response
curve for SA-57 (10 mg/kg).
A) PF-3845 (10 mg/kg) produced a leftward shift of the MJN110 substitution dose-response
curve. B) None of the drug combinations significantly decreased rates of responding. Values
represent mean ± SEM; n = 7-8 mice/group.
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Discussion
The present study demonstrates that mice readily learn to discriminate the dual FAAHMAGL inhibitor SA-57 from vehicle. Specifically, the majority (i.e., 23 of 24) of subjects
learned to discriminate the dual FAAH-MAGL inhibitor SA-57 from vehicle within 40 training
sessions. The 10 mg/kg SA-57 training dose was previously demonstrated to produce significant
increases in brain levels of AEA and 2-AG (Wiebelhaus et al., 2015). As SA-57 fully blocks
FAAH activity at lower doses (0.05-1 mg/kg) than those required to inhibit MAGL (1.25-12.5
mg/kg) (Niphakis et al., 2012) it provided a useful tool to examine the consequences of full
FAAH inhibition while incrementally elevating brain 2-AG. The observation that 1 mg/kg SA57, which produces maximal increases in endogenous AEA without detectable increases in 2-AG
(Niphakis et al., 2012), did not generalize to the training dose (10 mg/kg SA-57) indicates that
FAAH inhibition alone is not sufficient to occasion to the SA-57 training dose. Similarly, neither
FAAH inhibitor (i.e., PF-3845 or URB597) substituted for SA-57. In contrast, the dual FAAHMAGL inhibitor JZL195, and two MAGL inhibitors, MJN110 and JZL184, fully substituted for
the SA-57 training dose, suggesting that MAGL inhibition alone may be sufficient for
generalization to the 10 mg/kg SA-57 training dose. Interestingly, PF-3845 produced an
approximately two-fold leftward shift in the MJN110 substitution dose-response curve. The
observation that rimonabant completely blocked the discriminative stimulus effects of SA-57
indicates that CB1 receptors play a necessary role in the subjective effects of SA-57. Similarly,
rimonabant completely blocked the substitution of both MAGL inhibitors (MJN110 and JZL184)
and the dual FAAH-MAGL inhibitor JZL195. These findings suggest that elevating
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endocannabinoid brain levels through the simultaneous blockade of FAAH and MAGL produces
a CB1 receptor mediated interoceptive stimulus.
Consistent with previous studies reporting that SA-57 or the dual FAAH-MAGL inhibitor
JZL195 substitute for the THC discriminative stimulus (Long et al., 2009; Hruba et al., 2015;
Walentiny et al., 2015), we found that SA-57 (10 mg/kg) fully substituted for the discriminative
stimulus effects of the potent cannabinoid receptor agonist CP 55,940 in C57BL/6J mice and the
endogenous cannabinoid AEA (6 mg/kg) in FAAH (-/-) mice. The potency of SA-57 in
producing a discriminative stimulus was similar to its potency in substituting for either CP
55,940 or AEA. Furthermore, SA-57’s discriminative stimulus effects occurred at a training dose
known to produce maximal increases in AEA and 2-AG (Niphakis et al., 2012). In addition, CP
55,940 fully substituted for SA-57, an effect that was completely blocked by rimonabant, further
implicating a pivotal role of CB1 receptors in these effects. Similarly, the dual FAAH-MAGL
inhibitor JZL195 dose-dependently substituted for SA-57. Time-course investigation revealed
that SA-57 partially generalized at 0.5 h, fully generalized at 1 and 2 h, partially generalized at 4
h, and by 8 h mice responded mostly on the aperture paired with vehicle.
It is noteworthy that MJN110 and JZL184 fully substituted for the discriminative
stimulus effects of SA-57, while mice treated with a low dose of SA-57 (which does not elevate
2-AG), URB597, or PF-3845 selected the vehicle aperture. These findings suggest that MAGL
inhibition represents a driving force underlying the SA-57 training dose. However, the
observation that PF-3845 increased the potency of MJN110 to substitute for SA-57 suggests that
FAAH inhibition increases the effectiveness of the discriminative stimulus produced by MAGL
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inhibition alone. The fact that 2-AG levels are approximately three orders of magnitude higher
than AEA levels in wild type mouse brain (Ahn et al., 2009; Long et al., 2009) is consistent with
the notion that MAGL inhibition elicits more prominent pharmacological effects than those
produced by FAAH inhibition. Moreover, as FAAH is expressed on the post-synaptic terminal
(Gulyas et al., 2004), and MAGL (Dinh et al., 2002) is expressed on the pre-synaptic terminal, it
is plausible that AEA and 2-AG activate distinct CB1 receptor mediated neuronal circuits.
Because AEA and 2-AG bind CB1 and CB2 receptors, AEA also binds TRPV1 receptors,
and other FAAH substrates (i.e., PEA and OEA) bind PPARα receptors (Lo Verme et al., 2005),
we examined whether selective antagonists for each of these receptors would block the
discriminative stimulus effects of SA-57. Rimonabant, but not the other receptor antagonists,
completely blocked the discriminative stimulus effects of SA-57. These findings indicate that
CB1 receptor activation is required for the subjective effects of SA-57, while CB2, TRPV1, and
PPARα receptors are dispensable. Moreover, the fact that SA-57 did not affect ligand binding to
CB1 receptors in either a competitive or non-competitive manner is consistent with the
hypothesis that it increases brain endocannabinoid levels that then elicit a CB1 receptor-mediated
discriminative stimulus.
The present study also assessed whether a variety of psychoactive non-cannabinoid drugs
would substitute for SA-57. Specifically, nicotine did not substitute for the SA-57 training dose,
although it significantly reduced response rates. In contrast, diazepam partially substituted for
SA-57, but did so at a dose that reduced response rates. Similarly, diazepam partially substitutes
for THC at high doses that produce motor impairment in the rat drug discrimination paradigm
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(Wiley and Martin, 1999). Taken together, these studies suggest the possibility of a potential
GABAergic component for CB1 receptor-mediated discriminative stimuli. In addition, because
MAGL inhibition reduces brain levels of arachidonic acid as well as various prostanoids
(Nomura et al., 2011), we tested whether the COX2 inhibitor valdecoxib would substitute for
SA-57. However, valdecoxib was devoid of action in this assay, suggesting that prostaglandins
do not play a necessary role in the discriminative effects of SA-57.
It is noteworthy that combined inhibition of FAAH and MAGL attenuates somatic signs
of opioid withdrawal (Ramesh et al., 2011). However, simultaneous blockade of these enzymes
also elicits other cannabimimetic effects, as assessed in the tetrad assay including hypomotility,
antinociception, catalepsy, and hypothermia (Long et al., 2009; Anderson et al., 2014; Ghosh et
al., 2015), as well as impaired performance in a Morris water maze spatial memory task (Wise et
al., 2012). These effects of dual FAAH and MAGL inhibition are similar to those of THC,
whereas single inhibition of either enzyme produces a decreased spectrum and magnitude of
cannabimimetic effects. Specifically, the MAGL inhibitor JZL184 produces antinociception,
hypomotility, and dysregulation of thermoregulation when challenged with manipulations that
elicit hypothermia (Nass et al., 2015), while FAAH inhibition produces antinociception, but not
other cannabimimetic effects (Long et al., 2009). However, drug discrimination is more sensitive
in detecting cannabimimetic effects compared with the tetrad assay. For example, THC is more
potent in producing its discriminative stimulus effects than in eliciting the full set of tetrad
effects (Long et al., 2009; Marshell et al., 2014a). Given that dual blockade of FAAH and
MAGL significantly reduces locomotor activity (Long et al., 2009) and SA-57 (10 mg/kg)
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completely inhibits FAAH and MAGL activity (Niphakis et al., 2012), the lack of rate
suppressive effects of SA-57 (10 mg/kg) during training session is interesting. Similarly, THC
(5.6 mg/kg) reduces locomotor activity, but does not reduce response rates during training
sessions in drug discrimination procedure (Wiley et al., 2005). This lack of apparent motor
depression is consistent with the idea that rate suppressive effects of drugs undergo tolerance
throughout the course of drug discrimination training (Solinas et al., 2006).
The results of the present study suggest that SA-57 serves as a discriminative stimulus at
doses that produce increased levels of both AEA and 2-AG through a CB1 receptor mechanism
of action, though elevated levels of 2-AG may be the main driving force for the SA-57 training
dose. Although the brain regions mediating the discriminative stimulus effects of SA-57 and
cannabinoid receptor agonists are unknown, it is noteworthy that endogenous cannabinoids, and
their receptors are located in neural pathways mediating the reinforcing effects of drugs of abuse
(i.e. mesolimbic dopamine pathway) (Oleson and Cheer, 2012).
In conclusion, the present study demonstrates that the dual FAAH-MAGL inhibitor SA57 serves as a reliable discriminative stimulus. The observations that rimonabant completely
blocks the SA-57 training dose, and mice trained to discriminate SA-57, CP 55,940, and AEA
shows symmetrical substitution, strongly implicate the importance of the CB1 receptor in this
novel interoceptive stimulus. Collectively, these findings raise the provocative possibility that
FAAH and MAGL serve as dual brakes to prevent the psychoactive consequences of CB1
receptor over-stimulation caused by elevated levels of AEA and 2-AG.

92

Chapter 3. General Discussion

The first goal of this dissertation was to determine whether SA-57, a dual inhibitor of
FAAH and MAGL, which regulates levels of the endocannabinoids AEA and 2-AG will serve as
discriminative stimulus in the drug discrimination paradigm. To accomplish this goal, we
established SA-57 as a discriminative stimulus, and then evaluated if each enzyme target of SA57 (FAAH, MAGL, ABHD6) could substitute for the SA-57 discriminative stimulus. Until now,
an inhibitor of endocannabinoid degradation has not been established as a discriminative
stimulus. Then we determined the duration of action of the discriminative stimulus, and
investigated which receptors were necessary for generating the discriminative stimulus. Next, we
determined if inhibiting both FAAH and MAGL were required for generating the SA-57
discriminative stimulus, or if inhibiting either of these enzymes is sufficient. We discovered that
inhibiting FAAH or ABHD6 alone had no effect, but MAGL inhibition alone substituted for SA57 through a CB1 receptor mechanism. Moreover, FAAH inhibition enhanced the potency of the
MAGL inhibitor MJN110. In summary, the data from this dissertation indicate that FAAH and
MAGL serve as endogenous breaks that prevent endocannabinoid overstimulation of CB1
receptors. Also, the SA-57 discriminative stimulus can be used to examine potential subjective
effects produced by other inhibitors of endocannabinoid hydrolysis.
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5.1: Cross-substitution of SA-57 and CP 55,940
To select a training dose, we conducted a dose response study with SA-57 using two
cannabinoids (AEA and CP 55,940) that are reported to serve discriminative stimuli to determine
if SA-57 would substitute for either CP 55,940 (0.1 mg/kg) in C57BL/6J mice or AEA (5 mg/kg)
in FAAH-/- mice. SA-57 (10 mg/kg) fully substituted for both the CP 55,940 and AEA
discriminative stimulus, therefore, this dose of SA-57 (10 mg/kg) was selected to train a new
cohort of mice. After mice learned to discriminate SA-57 (10 mg/kg), we observed that JZL195,
and CP 55,940 fully substituted for SA-57. Because JZL195 is known to produce its behavioral
effects through the CB1 receptors (Long et al., 2009), the substitution of JZL195 for SA-57, and
cross-substitution between CP 55,940 and SA-57 provides strong evidence that CB1 receptors are
important for the SA-57 discriminative stimulus.

5.2: Investigating the receptors mediating the SA-57 discriminative stimulus
We evaluated whether the discriminative stimulus effects produce by SA-57 were
mediated by CB1, CB2, PPARα or TRPV1 receptors. The CB1 antagonist rimonabant (0.1 – 3
mg/kg) attenuated the SA-57 discriminative stimulus, but the lowest dose tested (0.03 mg/kg)
was without consequence. The lowest dose of rimonabant (0.03 mg/kg) resulted in 70% of
responses in the aperture paired with SA-57 indicating that as the dose of rimonabant decreased,
more AEA or 2-AG was available to stimulate CB1 receptors. It is interesting that lower doses of
rimonbant (0.1 - 1 mg/kg) completely blocked the discriminative stimulus, because these doses
have limited effects in other models of cannabinoid discrimination. For example, rimonabant (1
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mg/kg) partially, but not fully attenuated the discriminative stimulus effects of rats trained to
discrimination JWH-018 (0.3 mg/kg) (Wiley et al., 2014). In rats trained to discriminate WIN
55,212-2, rimonabant (1 mg/kg) shifts the dose effect curve without attenuating the WIN 55,2122 discriminative stimulus (Järbe et al., 2011). Given the diversity of effects among studies
investing the discriminative stimulus effects of cannabinoids, it is important to highlight one
major experimental condition in the present dissertation. The sample size of mice in the
rimonabant / SA-57 experiment (3-6 mice) was very small. This very small sample size may
have contributed to the all-or-none effects observed by the different doses of rimonabant.
The CB2 antagonists SR144528 had no effects on drug-like responding suggesting CB2
receptors are not involved in this novel discriminative stimulus. Because SA-57 inhibits FAAH,
and AEA binds PPARα and TRPV1 receptors in addition to degrading other Nacylethanolamines including N-palmitoylethanolamine (PEA), and N-oleoylethanolamine
(OEA), we administered selective antagonist of PPARα and TRPV1 receptors to determine if
either receptor contributed to the SA-57 discriminative stimulus. We selected antagonists of
PPARα and TRPV1 receptors that were found to be effective at attenuating the effects of OEA
and PEA in other behavioral assays (Lo Verme et al., 2005; Kinsey et al., 2009). We observed
no change in the substitution pattern of SA-57 in the presence of either antagonist, suggesting
PPARα and TRPV1 are not involved in the SA-57 discriminative stimulus. These findings along
with the CB1 antagonists study provide very strong evidence CB1 receptors are the sole driver in
the SA-57 discriminative stimulus. Also, CP 55,940 and MJN110 do not produce
pharmacological effects through PPARα or TRPV1, and each drug fully substitutes for SA-57,
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providing further evidence of the role of CB1 receptors.

5.3: Investigating the eCB degradative enzymes mediating SA-57’s effects
In the first part of this dissertation we established that mice could reliably learn to
discriminate SA-57 from vehicle. Our next goal was to determine if inhibiting FAAH, MAGL or
ABHD6 alone could substitute for SA-57, to determine the contribution of each enzyme in the
discriminative stimulus effects of SA-57.
JZL195 is another potent inhibitor of both FAAH and MAGL. Because the high dose of
JZL195 (20 mg/kg) fully blocks FAAH and MAGL activity, elevates AEA and 2-AG (Long et
al., 2009), and fully substituted for SA-57 (see figure 6) this supported the hypothesis that
inhibiting both FAAH and MAGL were required to produce the SA-57 discriminative stimulus.
However, until we examined selective inhibitors of each target of SA-57, it remained to be
discovered which enzymes were required. Therefore, we employed selective inhibitors of FAAH,
MAGL and ABHD6. The selective FAAH inhibitors (PF3845 and URB597) and the selective
ABHD6 inhibitors (KT195 and KT182) did not substitute for SA-57, however the MAGL
inhibitors (MJN110 and JZL184) fully substituted for SA-57, and was block by rimonabant. PF3845 did enhance the potency of MJN110 inhibition, which suggests that FAAH inhibition can
enhance the potency of MAGL inhibition. The observation that two MAGL inhibitors fully
substitute for SA-57 provides strong evidence that maximal inhibition of MAGL is sufficient to
produce subjective effects. Given that FAAH inhibition enhances the potency of MAGL
inhibition, the subjective effects of SA-57 are probably attributed to inhibiting both enzymes.
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The FAAH inhibitors PF-3845 and URB597 did not substitute for SA-57, and the mean
responses for both inhibitors were below 5% for the aperture paired with SA-57. Finally,
ABHD6 inhibitors did not substitute for SA-57. ABHD6 inhibition accounts for a small
percentage of 2-AG degradation but is expressed post-synaptically so it regulates 2-AG in closer
proximity to biosynthesis than MAGL, which is pre-synapatic.
Although FAAH inhibition does not substitute for SA-57, it produced a leftward shift in
the MJN110 dose response, which is likely the result of an increase in AEA binding to CB1
receptors. Because 2-AG levels are much higher than AEA levels in wild type mouse brain (Ahn
et al., 2009; Long et al., 2009), it is more reasonable to anticipate that a MAGL inhibitor on its
own would have a more robust effect than a FAAH inhibitor.

5.4: Nicotine and diazepam does not substitute for the SA-57 discriminative stimulus
As drug discrimination is considered a highly selective behavioral pharmacological assay
to investigate the receptor mechanism of action of drugs, we employed agonists that do not
stimulate CB1 receptors such as nicotine and diazepam. As expected, nicotine and diazepam did
not substitute for SA-57. However, diazepam did result in mean responses of 40% in the aperture
paired with SA-57, indicating partial substitution for the SA-57 discriminative stimulus. This is
similar to an older study observing partial substitution with GABA for THC (Mokler and
Rosecrans, 1989). This partial effect could be because CB1 receptors are localized on presynaptic GABA receptors. These observations indicate that drug discrimination is a useful
preclinical model used to assess drug receptor activity in vivo.
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5.5 Investigating the inhibition of arachidonic acid synthesis
Because MAGL is responsible for producing arachidonic acid and prostanoids in brain
(Nomura et al., 2011), we examined whether the COX-2 inhibitor valdecoxib, which reduces
prostanoid synthesis but does not affect brain endocannabinoid levels, would substitute for SA57. Valdecoxib produced minimal responses in the aperture paired with SA-57, suggesting that
prostaglandins do not play a necessary role in the discriminative effects of SA-57.

5.5 Final Discussion
Previous studies have examined the ability of FAAH and MAGL inhibitors to substitute
for the discriminative stimulus generated by direct CB1 agonists (i.e. THC and CP 55,940). The
purpose of the studies in this dissertation was to elucidate the effects of elevating endogenous
cannabinoids, via inhibition of the degradative enzymes FAAH and MAGL, to serve as a
discriminative stimulus. The present results support the hypothesis that elevating AEA and 2-AG
levels by inhibiting their primary serine hydrolases FAAH and MAGL serves as a discriminative
stimulus. The results presented here along with previous studies, indicate that endocannabinoid
catabolic enzymes produce subjective effects that mimic the effects of THC. The discriminative
stimulus effects of SA-57 were mediated via CB1 receptors with no contribution by CB2, TRPV1
or PPARα receptors.
We observed that complete blockade of MAGL substitutes for dual FAAH and MAGL
inhibition, thus MAGL inhibition may produce subjective effects on its own. In this dissertation,
the drug discrimination assay has provided valuable insights into the subjective effects produced
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by inhibiting both FAAH and MAGL independently or in combination. Thus, SA-57
discrimination in mice is a very useful assay to investigate the subjective effects produced by
inhibitors of endocannabinoid hydrolysis.
In summary, anandamide and 2-AG interact in a manner that is not fully understood to
produce a CB1 receptor mediated discriminative stimulus. Anandamide is reported to substitute
for THC, but only when exogenous administration of AEA is combined in the presence of a
FAAH inhibitor. Neither FAAH nor MAGL inhibitors produce THC-like subjective effects when
administered on their own. However, increasing levels of endogenous anandamide and 2-AG
mimics the effects of THC.

5.6: Future Studies
Given that MAGL inhibitors substitute for SA-57, it would be interesting to determine if
MAGL inhibition alone can serve as a discriminative stimulus. This would provide an
opportunity to directly investigate the subjective effects of MAGL inhibition as an alternative to
administering MAGL inhibitors in mice trained to discriminate SA-57 or THC. To fully
characterize the discriminative stimulus effects produced by the major endocannabinoid
regulating enzymes, we would also need to determine if mice could discriminate a FAAH
inhibitor. If a FAAH inhibitor serves as a discriminative stimulus, it would provide “direct
evidence” that FAAH inhibition produces subjective effects. Given that FAAH inhibitors do not
substitute for the discriminative stimulus effects of THC or SA-57 and do not produce the full
subset of tetrad effects, we predict that a FAAH inhibitor would not serve as a discriminative
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stimulus. Because MAGL inhibitors fully substitute for SA-57, it is likely that a MAGL inhibitor
would serve as a discriminative stimulus. If complete blockade of MAGL serves as a
discriminative stimulus, it would indicate MAGL inhibition produces subjective properties on its
own, but these effects may not completely overlap with THC. Importantly, FAAH does not
produce down regulation of CB1 receptors. The lack of subjective properties without functional
changes to the CB1 receptor could indicate potential therapeutic benefits of FAAH inhibition
without producing abuse-related subjective effects.
2-AG is reported to induce rapid increases in intracellular free Ca2+ concentrations in
NG108-15 cells by stimulating CB1 receptors (Sugiura et al., 1999). Therefore, we know that 2AG binds CB1 receptors, however, we cannot measure changes in the binding of endogenous
cannabinoids to CB1 receptors after inhibiting endocannabinoid hydrolysis. In contrast, we can
measure changes in the binding of CP 55,940 by determining the amount of ligand that displaces
[3H] CP 55,940, but we can’t measure how much AEA or 2-AG displaces [3H] CP 55,940 after
administering SA-57. This capability would allow us to determine the amount of AEA and 2-AG
that binds to CB1 receptors after inhibiting endocannabinoid hydrolysis. For example, we would
be able to determine the specific levels of AEA and 2-AG that is needed to bind CB1 receptors to
generate a discriminative stimulus, or substitute for a separate discriminative stimulus.
Also, it is yet to be determined which neural substrates are important for producing drug
discriminative stimuli. Although, previous studies that conducted direct infusions of drug into
specific brain regions have provided some insight into the brain regions that may be necessary
for generating a discriminative stimulus. For example, nicotine infused directly into the medial
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pre-frontal cortex (mPFC) fully substitutes for systemic injections of nicotine in the rat (Miyata
et al., 1999). In a different study, two of six rats trained to discriminate i.p. injections of THC
from vehicle selected the drug appropriate lever when THC was infused into the PFC or dorsal
hippocampus (Mokler and Rosecrans, 1989). Also, infusions of vehicle into the reticular
formation resulted in responses for THC indicating non-specific stimulation of this brain region
can produce a THC-like discriminative stimulus. It is important to note that cannulae placements
were not reported in this study. A similar approach could be taken in the future with mice trained
to discriminate SA-57 using surgically implanted cannula aimed at the mPFC. Then we could
infuse SA-57 into the mPFC to determine if the mPFC is necessary to generate discriminative
stimulus produced by cannabinoids.
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